Structural and functional characterization of the interactions of platelet derived chemokines CCL5, CXCL4 and CXCL4L1 by Sarabi, Alisina
 
 
Structural and Functional Characterization 
of the Interactions of Platelet-Derived Chemokines 
CCL5, CXCL4 and CXCL4L1 
 
 
 
Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der Rheinisch-
Westfälischen Technischen Hochschule Aachen zur Erlangung des akademischen Grades 
eines Doktors der Naturwissenschaften genehmigte Dissertation  
vorgelegt von 
 
Diplom-Biologe 
Alisina Sarabi 
aus 
Kabul, Afghanistan 
 
 
 
Berichter: 
Universitätsprofessor Christian Weber 
Universitätsprofessor Rainer Fischer 
 
Tag der mündlichen Prüfung: 31.01.2011 
 
 
 
 
Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfügbar. 
 II 
 
The results of this work were in part published in: 
 
 
Rory R Koenen, Philipp von Hundelshausen, Irina V Nesmelova, Alma Zernecke, Elisa A 
Liehn, Alisina Sarabi, Birgit K Kramp, Anna M Piccinini, Søren R Paludan, M Anna 
Kowalska, Andreas J Kungl, Tilman M Hackeng, Kevin H Mayo & Christian Weber 
(2009). Disrupting functional interactions between platelet chemokines inhibits 
atherosclerosis in hyperlipidemic mice. Nat Med 15 (1): 97-103. 
 
 
Alisina Sarabi, Birgit K Kramp, Maik Drechsler, Tilman M Hackeng, Oliver Soehnlein, 
Christian Weber, Rory R Koenen and Philipp von Hundelshausen (2010). CXCL4L1 
inhibits angiogenesis and induces undirected endothelial cell migration without affecting 
endothelial cell proliferation and monocyte recruitment. J Thromb Haemost 9 (1): 209-19 
[Epub ahead of print DOI:10.1111/j.1538-7836.2010.04119.x.] PMID: 20961394. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents 
 
 i 
Table of Contents 
Table of contents…………………………………………………………...…………….i 
Abbreviations…………………………………………………………………….............vi 
 
I Introduction ........................................................................................................... 1 
I.1 Atherosclerosis ...................................................................................................... 1 
I.2 Chemokines ........................................................................................................... 2 
I.3 Interaction of chemokines ..................................................................................... 4 
I.4 Chemokine receptors ............................................................................................. 6 
I.4.1 Alternative signaling mechanism ............................................................... 8 
I.5 Platelets.................................................................................................................. 8 
I.6 Platelet-derived chemokines CXCL4, CXCL4L1 and CCL5 ............................. 10 
I.6.1 CXCL4 ..................................................................................................... 10 
I.6.2 CXCL4L1 ................................................................................................. 14 
I.6.3 CCL5 ........................................................................................................ 15 
I.7 Aims of the study................................................................................................. 17 
II Material and methods .......................................................................................... 18 
II.1 General equipment............................................................................................... 18 
II.2 Molecular biology ............................................................................................... 19 
II.2.1 General work with E. coli......................................................................... 19 
Bacteria growth media.............................................................................. 20 
Preparation of heat-shock competent E. coli ............................................ 20 
Table of Contents 
 
 ii 
Heat-shock transformation of competent E. coli ...................................... 21 
II.2.2 Bacterial strains ........................................................................................ 21 
II.2.3 Plasmids.................................................................................................... 21 
II.2.4 Polymerase chain reaction ........................................................................ 21 
II.2.5 Cloning of CXCL4 and CXCL4L1 .......................................................... 22 
II.2.6 Miniprep: Small-scale purification of plasmid DNA ............................... 23 
II.2.7 Midiprep and maxiprep: Large-scale purification of plasmid DNA ........ 24 
II.2.8 Restriction endonuclease digestion of DNA ............................................ 24 
II.2.9 Agarose gel electrophoresis...................................................................... 24 
II.2.10 Quantification of DNA ............................................................................. 25 
II.2.11 Sequencing of DNA ................................................................................. 25 
II.3 Protein analysis.................................................................................................... 25 
II.3.1 Protein concentration assay ...................................................................... 25 
II.3.2 SDS-polyacrylamide gel electrophoresis (PAGE) ................................... 26 
II.3.3 Tricine gel................................................................................................. 27 
II.3.4 Coomassie blue staining ........................................................................... 28 
II.3.5 Silver staining........................................................................................... 28 
II.3.6 Western blot analysis................................................................................ 28 
II.3.7 Dot blot ..................................................................................................... 29 
II.3.8 Primary antibody ...................................................................................... 29 
II.3.9 Secondary antibody .................................................................................. 30 
II.4 Protein expression and purification ..................................................................... 30 
II.4.1 CCL5 expression and purification............................................................ 30 
II.4.2 CCL5 FPLC (fast protein liquid chromatography) .................................. 31 
Sephacryl S-100HR .................................................................................. 31 
HiTrap chelating HP................................................................................. 31 
MonoS™ 5/50 GL ..................................................................................... 32 
Resource™ Reverse Phase Chromatography (RPC) ................................. 32 
Table of Contents 
 
 iii 
II.4.3 CCL5 HPLC (high performance liquid chromatography)........................ 33 
II.4.4 CXCL4 and CXCL4L1............................................................................. 34 
II.4.5 CXCL4 and CXCL4L1 FPLC .................................................................. 34 
HiLoad 16/10 SP-Sepharose™ .................................................................. 34 
MonoS™ 5/50 GL or Capto™ S ................................................................. 35 
Resource™ RPC ........................................................................................ 35 
II.4.6 CXCL4 and CXCL4L1 HPLC ................................................................. 35 
II.4.7 Chemical synthesis of CXCL4L1............................................................. 36 
Peptide synthesis and native chemical ligation ........................................ 36 
II.5 Biochemical analysis of the CCL5-CXCL4 heterodimer.................................... 39 
II.5.1 Molecular dynamics simulations .............................................................. 40 
II.5.2 Differential scanning calorimetry............................................................. 40 
II.5.3 Interaction of CXCL4 or CXCL4L1 with CCL5 ..................................... 41 
Ligand blot................................................................................................ 41 
Isothermal fluorescence titration .............................................................. 41 
II.6 Cell culture .......................................................................................................... 42 
II.6.1 General ..................................................................................................... 42 
II.6.2 Cell lines ................................................................................................... 42 
II.6.3 Culturing of adherent cell monolayers ..................................................... 42 
II.6.4 Culturing of cells in suspension ............................................................... 43 
II.6.5 Freezing and thawing of cells................................................................... 43 
II.7 Functional assays................................................................................................. 43 
II.7.1 Angiogenesis in vitro................................................................................ 43 
II.7.2 Endothelial migration ............................................................................... 43 
Transwell assay ........................................................................................ 43 
Table of Contents 
 
 iv 
The µ-Slide Chemotaxis chamber ............................................................ 44 
II.7.3 Endothelial cell proliferation.................................................................... 44 
II.7.4 Monocyte recruitment............................................................................... 45 
In vitro ...................................................................................................... 45 
In vivo....................................................................................................... 45 
II.7.5 Heparin neutralization .............................................................................. 46 
II.7.6 Protein C activation .................................................................................. 46 
II.7.7 Data illustration and statistic analysis ...................................................... 46 
III Results ................................................................................................................. 47 
III.1 Protein expression and purification ..................................................................... 47 
III.1.1 Expression and purification of recombinant CCL5.................................. 47 
III.2 NMR chemical shift mapping of CCL5-CXCL4 heterodimer ............................ 51 
III.3 CXCL4/CXCL4L1 Purification .......................................................................... 54 
III.4 Chemical synthesis of CXCL4L1........................................................................ 59 
III.5 Functional analysis of CXCL4L1 and CXCL4 ................................................... 64 
III.5.1 CXCL4L1 and CXCL4 inhibit tube formation ........................................ 64 
III.5.2 CXCL4L1 induces endothelial cell chemokinesis.................................... 65 
III.5.3 CXCL4L1 does not inhibit endothelial cell proliferation......................... 66 
III.5.4 Hetero- and homooligomerization differ in CXCL4L1 and CXCL4 ....... 67 
III.5.5 CXCL4L1 interaction with CCL5 does not enhance CCL5-triggered ........
  monocyte arrest ........................................................................................ 69 
III.5.6 Influence of CXCL4L1 on heparin neutralization and APC generation .. 70 
IV Discussion............................................................................................................ 72 
IV.1 Different expression strategies for obtaining the CCL5, CXCL4 and ...................  
 CXCL4L1 ............................................................................................................ 72 
Table of Contents 
 
 v 
IV.2 Structural differences between CXCL4 and CXCL4L1...................................... 74 
IV.3 CXCL4-CXCL4L1 functional comparison ......................................................... 75 
V Summary.............................................................................................................. 80 
VI Zusammenfassung ............................................................................................... 82 
VII Acknowledgement ............................................................................................... 84 
VIII References ........................................................................................................... 85 
IX Curriculum Vitae ................................................................................................. 93 
 
Abbreviations 
 
 vi 
Abbreviations 
aa  amino acid 
APC  activated protein C 
apoE  apolipoprotein E 
APS  ammonium persulfate 
aPTT  activated partial thromboplastin time 
bFGF  basic fibroblast growth factor 
BMC  1,2-bis(2-mercaptoacetamido) cyclohexane 
CAD  coronary artery disease 
CD  cluster of differentiation 
CVD  cardiovascular disease  
DDT  dithiothreitol 
DMF  dimethylformamide 
DMSO dimethylsulphoxid 
E. coli  Escherichia coli 
ECMs  extracellular matrix proteins 
FCS  fetal calf serum 
Fmoc  9-Fluorenylmethoxycarbonyl 
FPLC  fast protein liquid chromatography 
GAG  glycosaminoglycan 
GDP  guanosine diphosphat 
Gnd-HCL guanidine-HCL 
GPCR  G-protein-coupled receptors 
GTP  guanosine triphosphat 
HDMEC human dermal microvascular endothelial cells 
Abbreviations 
 
 vii 
HEPES 4-2-hydroxyethyl-1-piperazineethanesulfonic acid 
HF  hydrofluoric acid 
HPLC  high pressure liquid chromatography 
HRP  horseradish peroxidase 
HSA  human serum albumin 
HSQC  15N-1H heteronuclear single quantum coherence 
HUVEC human umbilical vein endothelial cell 
IFN-γ  interferon-gamma 
IMAC  immobilized metal affinity chromatography 
IP3  inositol triphosphate 
IPTG  isopropyl-β-D-thiogalactopyranoside 
Kd  dissociation constant 
kDa  kilo Dalton 
LB  Lauria-Bertani broth 
LDL  low-density lipoprotein 
MAPK mitogen-activated protein kinase 
MBHA methylbenzhydrylamine 
MM6  mono mac 6 
MPA  mercaptoproprionic acid 
NMR  nuclear magnetic resonance 
o.n.  over night 
PBS  phosphate buffered saline 
PF4  platelet factor 4 
PI3K  phosphoinositide-3 kinase 
PIP2  phosphatidylinositol bisphosphate 
PIP3  phosphotidylinositol-3,4,5-trisphosphate 
Abbreviations 
 
 viii 
PKA  protein kinase A 
PKC  protein kinase C 
PLC  phospholipases C 
PMN  polymorphonuclear cells 
RANTES regulated on activation, normal T-cell expressed and secreted 
rt  room temperature 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SPPS  solid-phase peptide synthesis 
TB  terrific broth 
t-Boc  tert-Butyloxycarbonyl 
TBS  tris buffered saline 
TEMED N,N,N′,N′-tetramethylethylenediamine 
TFA  trifluoroacetic acid 
TM  thrombomodulin 
TNF-α  tumor necrosis factor-alpha 
TSS  transformation and storage solution 
VEGF  vascular endothelial growth factor 
VWF  von Willebrand factor 
 
I  Introduction 
 1 
I Introduction 
I.1 Atherosclerosis 
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in developed 
countries, thus imposing an already substantial and still increasing socio-economic burden 
(Koenen 2008). Atherosclerosis, which can be best characterized as a chronic 
inflammation of the vessel wall, is the underlying cause of coronary artery disease (CAD). 
Recent developments in vascular biology have shown that lesion progression in 
atherosclerosis is driven by the influx of inflammatory cells from the blood stream 
(Hansson 2006) . 
Atherosclerosis is characterized as a chronic inflammation, where due to endothelial 
dysfunction and production of pro-inflammatory mediators by platelets, monocytes are 
recruited to the surface of endothelial cells (Fig.I.1 A). Ensuing the transmigration through 
the endothelial layer into the intima, monocytes transform to macrophages and further to 
foam cells through engulfing and accumulating lipids (Fig.I.1 B). More inflammatory cells 
are attracted and a lipid-rich and necrotic core (plaque) is formed. Neovascularization, 
which emerges from the adventitia into the plaque, is responsible for leakage of blood 
components and hemorrhage (Fig.I.1 C). The progression of the plaque formation leads to 
the formation of a fibrous cap, which is composed of collagen rich extracellular matrix, T 
cells, macrophages and smooth muscle cells that overlay the plaque. Proteases that are 
released from the activated immune cells weaken the fibrous cap and this can lead to the 
rupture of the plaque. The exposure of cell debris and tissue factor to the blood triggers the 
coagulation cascade, which finally ends in the formation of thrombosis and occlusion of 
the artery (Fig.I.1 D) (Weber 2008). 
Chemokines appear to play an important role in the regulation and control of this process 
by orchestrating the interactions between circulating blood cells and arterial wall. 
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Fig.I.1: Development of atherosclerosis. (A) Endothelial-cell dysfunction leads to early platelet and 
leukocyte adhesion and increased permeability of the endothelium. (B) Recruited monocytes accumulate 
lipids and transform into macrophages or foam cells (fatty streaks). (C) Creation of a necrotic core by 
apoptosis of macrophages and other plaque cells. A fibrous cap formation that consists of matrix and a 
smooth-muscle-cell layer is formed. Also neovascularization can occur from the adventitia within the plaque, 
which can lead to plaque hemorrhage. (D) Progression of the plaque leads to a thinning of the fibrous cap, 
which can ultimately results in plaque rupture due to matrix degradation by proteases (Weber 2008). 
 
I.2 Chemokines 
Chemokines (an abbreviation of chemoattractant cytokines) are a family of structurally 
related proteins which can influence the most profound aspects of a cell’s life, including 
not only activation, adhesion and chemotaxis but also proliferation, maturation, 
differentiation, apoptosis, malignant transformation, and dissemination (Rossi 2000). They 
are single polypeptides ranging from 70 to 100 amino acids in length, approximately 8 to 
10 kDa in molecular weight and share 20-50% gene and amino acid sequence homology. 
The chemokines are classified into four subfamilies according to the position of the N-
terminal cysteines. The α-chemokines, also known as CXC chemokines, contain a single 
random amino acid between the first and second cysteine residues (Kobayashi 2006). Up to 
 2 
I  Introduction 
 3 
now 17 different CXC chemokines have been described. This group can be further divided 
into chemokines containing the amino acid motif glutamic acid-leucine-arginine (ELR-
positive) at the N-terminus and those without the motif (ELR-negative). An example for an 
ELR-positive chemokine is CXCL8 (IL-8) and for an ELR-negative chemokine CXCL4 
(Platelet Factor 4, PF4). β or CC chemokines have two adjacent cysteine residues near the 
N-terminus. At least 28 chemokines are allocated to this group e.g. CCL5 or RANTES 
(Regulated on activation normal T cell expressed and secreted) (Charo 2004). The C or γ 
group has two members XCL1 (lymphotactin-α) and XCL2 (lymphotactin-β) which lacks 
two of the four cysteines, but shares homology at its carboxyl terminus with the C-C 
chemokines (Kelner 1994). CX3CL1 (Fractalkine) is a C-X3-C chemokine with three 
random amino acid residues between the first two cysteines and constitutes alone the 
fourth subgroup. CX3CL1 is the only chemokine besides CXCL16 that can be found as 
membrane bound whereas the rest is soluble. 
Previously, chemokines were divided broadly into two categories according to their 
function in pro-inflammatory and homeostatic chemokines (Moser 2004). Pro-
inflammatory chemokines act in a SOS response where they are expressed by induction of 
a stimulus that alters the cellular homeostasis and are responsible for the recruitment of 
immune cell to the site of the inflammation and infection. Whereas the homeostatic 
chemokines are expressed constitutively and play an important role in basal leukocyte 
trafficking and forming the architecture of secondary lymphoid organs (Gerard 2001). 
Recent findings indicate that many chemokines cannot be classified in either of these 
groups. Such chemokines with dual function participate in immune defense functions as 
well as in targeting non-effector leukocytes at sites of leukocyte development and immune 
surveillance. Many chemokines with dual-function are highly selective for lymphocytes 
and have a role in T-cell development in the thymus, as well as in T-cell recruitment to 
sites of inflammatory (Moser 2004). Although there are numerous of chemokines, 
structurally they are similarly shaped (Fig.I.2). 
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Fig.I.2: Typical 3D structure of a CXC (CXCL4) and CC (CCL5) chemokine. The chemokine topology 
consists of an elongated N-terminus followed by first two cysteines. A loop of about ten residues shapes the 
N loop, which has an important functional role. Then after the three anti-parallel β-strands a C-terminal α-
helix is succeeded. Each β-strand unit is connected by turns known as the 30s, 40s and 50s loops, which 
reflects the numbering of residues in the mature protein. The 30s and 50s loops possess the latter two of the 
four cysteines characteristic of the family of CXC chemokines (generated with 3D-Mol Viewer). 
 
I.3 Interaction of chemokines 
Chemokines can form heterophilic interactions, which then can lead to enhancement or 
suppression of the primordial function. Moreover a functional chemokine ‘interactome’ 
(protein-protein interaction) can be constituted by different interactions in particular 
microenvironments, where a given chemokine could exercise different functions dependent 
on the composition of a specific milieu and dependent on the interaction partner. These 
interactions can expand the plasticity of the regulatory chemokine network, which can 
evoke the possibility of regulating and orchestrating of the leukocytes to the inflammatory 
sites (Weber 2006). It has been reported that the heterodimerization of CCL3 and CCL4 
protects them from enzymatic digestion thus stabilizing their activity or might induce 
receptor heterodimerization to affect signaling (Guan 2001). The CCR7 agonists CCL19 
and CCL21 can form heterodimers with unrelated non-agonist chemokines 
(CCL19/CCL22 or CCL21/CXCL13) which can lead to the activation of CCR7 at lower 
agonist concentrations than in the presence of CCL19 or CCL21 alone (Paoletti 2005). 
Other examples for heterophilic interaction are CXCL4 with CXCL8 (Dudek 2003; 
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Nesmelova 2005) or CXCL4 with CCL5 (von Hundelshausen 2005). There are two types 
of interactions between CC and CXC chemokines, the CC-type and the CXC-type. In the 
CC-type the N-termini from two monomer subunits are involved in the interaction forming 
a small β-sheet (Sticht 1999). In the CXC type, the first β-strand from each monomer 
subunit interacts with the first β-sheet of the other monomer subunit in an extended six-
stranded β-sheet domain (Clore 1995). 
 
Chemokines also form robust interactions with GAGs (glycosaminoglycan) of the 
extracellular matrix and endothelial cell (Kuschert 1999). There are several classes of 
GAGs, the most ubiquitous being HS (heparan sulfate), a polysaccharide that is expressed 
on virtually every cell in the body and comprises 50–90% of total endothelial 
proteoglycans (Proudfoot 2006). Other classes of GAGs include heparin, which is 
produced almost exclusively by mast cells and has been exploited therapeutically as an 
anticoagulant, chondroitin sulfate and dermatan sulfate, which, like HS, are found on cell 
surfaces and the extracellular matrix, keratan sulfate and hyaluronic acid, which have 
important supportive skeleton functions. A common feature of GAGs is their overall 
negative charge due to the sulfate and carboxylate groups, which suggests an electrostatic 
interaction with cationic basic proteins, such as chemokines. However, while the driving 
force for binding is principally electrostatic, this interaction is not only based on overall 
charge interactions, because also acidic chemokines like CCL3 or CCL4 interact with 
GAGs (Kuschert 1999). 
A common heparin-binding motif for several chemokines has been described as a classical 
BBXB motif, where B represents a basic amino acid residue, on the 40s loop for example 
for CCL5, CCL3 and CCL4 (Proudfoot 2006). GAG binding is a prerequisite of 
chemokine activity in vivo because of the creation of a high local concentration of 
chemokines by retention on the luminal lining of the vessel. Without this tethering 
mechanism, chemokine accumulation would be hampered by diffusion, especially under 
flow conditions, diluted to a concentration below the threshold required for binding, and 
distributed uniformly throughout the vasculature. Thus no localized chemotactic signal 
would be generated for leukocytes to follow. GAGs, that are present on the cell surface, 
facilitate also oligomerization of chemokines to enhance luminal presentation (Hoogewerf 
1997). Furthermore, it has been shown that chemokines with mutations in the GAG 
binding site lose their ability to recruit monocytes in vivo, even though the chemotactic 
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activity in vitro is retained (Proudfoot 2003). This demonstrates that interaction with 
GAGs in vivo is essential, and further show that GAG interaction and oligomerization are 
closely linked features of chemokines.  
 
I.4 Chemokine receptors 
Chemokines act through rhodopsin-like, class A, seven-transmembrane-domain (7TMD), 
G-protein coupled receptors (GPCR). These chemokine receptors are part of a much bigger 
superfamily of G-protein coupled receptors that include receptors for hormones, 
neurotransmitters, paracrine substances, inflammatory mediators, certain proteinases, 
pheromones, taste, odorant molecules, and even photons and calcium ions (Murdoch 
2000). 
According to their ligands (e.g. CXC-, CC-chemokine) that they bind, chemokine receptors 
are classified into 4 groups, CXCR, CCR, XCR and CX3CR. Up to date 7 CXCR, 10 CCR, 
1 XCR and CX3CR receptor family members are known. Each chemokine receptor has 
distinct chemokine specificity, but the specificities can overlap considerably, because 
many chemokines can bind multiple receptor subtypes, and many receptors can bind 
multiple chemokines (Murphy 2000). Nevertheless, binding of CC-chemokine receptors is 
restricted to CC-chemokines and the same holds true for CXC-chemokine receptors. 
The receptors have a length of 320-370 amino acids (aa) and show a 25-80% aa sequence 
identity, indicating a common ancestor. Moreover they share some common features 
including an acidic extracellular N-terminal segment with tyrosine sulfation motif, a 7 α-
helical transmembrane domain with 3 intracellular and 3 extracellular connecting loops 
composed of hydrophilic amino acids that are oriented perpendicularly to the plasma 
membrane. Highly conserved cysteines in extracellular loops 1 and 2 are linked by a 
disulfide bond. The sequence DRYLAIVHA, or slight variations, in the second 
intracellular loop as well as a basic third intracellular loop and a cysteine in each of the 
four extracellular domains are also present in all the receptors. The intracellular C-terminal 
segment is rich with serine and threonine residues (Fig.I.4) (Murphy 2000). 
Chemokine GPCRs carry out three fundamental parts of the chemokine-induced “cellular 
reflex”: message acquisition, semantic extraction (decoding), and initiation of cell 
responses (Rot 2004). Sequence analysis of the chemokine receptors shows high 
homology, except for the N-terminal and C-terminal residues. Low sequence homology 
among the receptor N-terminal residues suggests that the N-domain is involved in ligand 
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binding, and play a direct role in mediating ligand specificity whereas the cytoplasmic C-
terminal tail contains serine and threonine residues as potential phosphorylation sites, 
which are important for the regulation of the receptor activity. The ligand-receptor 
interaction is based on a general two-site mechanism model. Binding involves interactions 
between the ligand N-loop and receptor N-domain (site-I), and ligand N-terminal and 
receptor exoloop residues (site-II) (Rajagopalan 2006). 
 
 
Fig.I.4: Topology of a typical chemokine receptor.  A G-protein coupled receptor is composed of an 
extracellular N-terminus followed by sequential changes of the intracellular loops and extracellular loops 
(ECL1-3) which are connected by the hydrophobic transmembrane domains (TM1-TM7) embedded in the 
bilayer of the cell surface, ending with an intracellular C-terminal tail (Fernandez 2002). 
 
After agonist binding, GPCRs expose intracellular sites involved in the interaction with the 
G-protein heterotrimer, which contains α, β and γ subunits. This catalyses the dissociation 
of GDP bound to the Gα subunit and its replacement with GTP, and leads to dissociation of 
Gα from Gβγ subunits. Chemokine receptors can be coupled to several different Gα 
isotypes. Both α-GTP subunits and Gβγ subunit complexes then stimulate several 
downstream effectors. For example chemokines that mediate signals through the pertussis 
toxin-sensitive Gαi proteins activate the phosphoinositide-3 kinases (PI3K), which then 
leads to generation of phosphotidylinositol-3,4,5-trisphosphate (PIP3), which then further 
activates other signal transduction component that results finally in chemotaxis (Rot 2004). 
Other downstream signaling molecules are for example, phospholipases C (PLC), 
phosphatidylinositol bisphosphates (PIP2), inositol triphosphate (IP3) and proteinkinase C 
(PKC) that results in the MAPK cascade activation cascades that regulates the nuclear 
expression of growth-promoting genes. Ultimately, the G-protein-coupling specificity of 
each receptor determines the nature of its downstream signaling targets (Dorsam 2007). 
The simultaneous presence of two different chemokines can induce homo- or 
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heteromerization of the receptors. In the case of heteromerization, distinct signaling can be 
triggered through another G protein subunit (Rodríguez-Frade 2001). 
 
I.4.1 Alternative signaling mechanism 
An outside-in signaling of chemokines can be mediated also by binding to sulfated sugars 
of the GAG family, such as heparan sulfate and chondroitin sulfate on the surface of cells. 
For example, CCL5 signals in HeLa-CD4 cells that express GAGs and are completely 
devoid of GPCRs, but does not signal in mutant cells that lack GAGs (Chang 2002). This 
GPCR-independent signal was mediated by GAG-decorated CD44 (Roscic-Mrkic 2003). 
CXCL4 may also signal through chondroitin sulfate-decorated membrane molecules on 
neutrophils, monocytes, and lymphocytes (Brandt 2000). GAGs on a target cell membrane 
may also influence chemokine signals by another mechanism, for example by facilitating 
GAG bound chemokines the presentation to their GPCRs in cis by GAG binding-induced 
changes in their secondary structure.  
 
I.5 Platelets 
Platelets are small, 2-3 µm in diameter, anuclear megakaryocyte-derived cells that lack 
genomic DNA but contain megakaryocyte-derived messenger RNA (mRNA) and the 
translational machinery needed for protein synthesis. Pre-mRNA splicing, a typical nuclear 
function, has been detected in the cytoplasm of platelets and the platelet transcriptome 
contains approximately 3000 to 6000 transcripts. After leaving the bone marrow, platelets 
circulate in the blood system for about 10 days (Davi 2007). Platelets play an important 
role in thrombosis and hemostasis. Mature platelets patrol through the circulation in an 
inactive state and are cleared after 8-10 days by macrophages in the spleen and liver (Von 
Hundelshausen 2008). Their contact with macromolecules, such as von Willebrand factor 
(VWF) and subendothelial extracellular matrix proteins (ECMs), of the injured vessel wall 
or constituents of a ruptured atherosclerotic plaque entails activation, aggregation, and 
adhesion through various receptors (Varga-Szabo 2008). While these events help to 
prevent blood loss in the case of injury, they are the initial steps of thrombus formation and 
can induce acute arterial occlusion. Receptors on the platelet surface are the initiators of 
activation signaling and subsequent platelet activities. Most of the platelet-activating 
signals rely on the binding of agonists to G-protein coupled receptors (Offermanns 2006). 
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After platelet activation multiple cellular responses are mediated, including the release of 
granule contents and formation of microparticles. A considerable portion of the secretory 
proteins and ingredients are multiple chemokines that are stored in the α-granules (von 
Hundelshausen 2007). These products play an important role in the protective hemostasis 
as well as in the pathologic thrombus formation (Jennings 2009). For the many platelet-
derived substances, chemokines are an especially intriguing family of proteins that are 
stored in their α-granules and exert numerous biological activities (von Hundelshausen 
2007). A variety of chemokines has been found to be expressed by platelets (Table 1) share 
characteristic chemicophysical properties, e.g. a positive charge and high affinity for 
negatively charged glycosaminoglycans which enables their retention on the surface of 
endothelial cells even in the presence of shear forces (Baltus 2005). They are involved in 
the adhesion and transmigration of monocytes, PMN (polymorphonuclear cells), and bone 
marrow derived progenitor cells in the vessel wall. In addition they participate in the 
process of forming and extending atherosclerotic plaques (Davi and Patrono 2007). Among 
them, the most abundant are CXCL4 (PF4), CXCL7 (CTAP-III), CCL5 (RANTES), and 
CXCL-12 (SDF-1). Platelet chemokines do not form only homo-aggregates, but also 
heterophilic interactions occur, which leads to significant modulation of their biological 
activities (Weber and Koenen 2006). 
 
Tab.1: Chemokines known to be stored in platelets. 
Chemokine Alternative name Receptor System 
CXCL1 GRO-α CXCR2, 
CXCR1 
human 
CXCL4 PF4 GAG, 
CXCR3B 
human, mouse 
CXCL4L1 PF4alt Unknown human 
CXCL5 ENA-78 CXCR2 human 
CXCL7 PBP, CTAPIII 
NAP-2, β-TG 
CXCR2 human 
CXCL8 IL-8 CXCR1, 
CXCR2 
human 
CXCL12 SDF-1α CXCR4 human, mouse 
CCL2 MCP-1 CCR2 human, mouse 
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Chemokine Alternative name Receptor System 
CCL3 MIP-1α CCR1 Human 
CCL5 RANTES CCR1, CCR3, 
CCR4, CCR5 
human, mouse 
CCL17 TARC CCR4, CCR8 human 
 
I.6 Platelet-derived chemokines CXCL4, CXCL4L1 and 
CCL5 
I.6.1 CXCL4 
Platelet factor 4 (PF4) or CXCL4 is an abundant platelet α-granule protein that is a 
founding member of the CXC chemokine family. CXCL4 was one of the first chemokines 
to be discovered (Deuel 1977). For a certain time, CXCL4 expression and storage was 
solely believed to occur in megakaryocytes and the α-granules in platelets. Expression has 
also been shown in other different cell types including monocytes, T cells, neutrophils and 
smooth muscle cells (Lasagni 2007). The human CXCL4 gene encodes a protein of 70 
amino acids and is located on chromosome 4q13.3 (Zlotnik 2006). Although CXCL4 was 
the first chemokine that was isolated, unlike other chemokines, it may not have a clear role 
in inflammation, since it does not behave like a “classic” chemokine exerting no significant 
chemotactical properties on immune cells. And also unlike most CXC-chemokines, 
CXCL4 does not contain an N-terminal Glu-Leu-Arg (ELR) motif, which is critical for the 
activation of the chemokine receptor CXCR2 and for the promotion of angiogenesis 
(Strieter 1995). Only at concentrations several orders of magnitude higher than those of 
other prototypic members of this family, e.g. CXCL8 (interleukin 8, IL-8) CXCL4 has 
chemotactic and functional priming activity on neutrophils (Petersen 1998). Despite its 
relative impotence as a chemotaxin, CXCL4 has pleiotropic activities. The most salient 
feature of this abundant protein (20 mg/109 platelets) is its high affinity for the anionic 
heparin (Kd 4.4 nM) (Dudek 1997), which can lead to HIT (heparin induced 
thrombocytopenia), an immune mediated reaction in which auto-antibodies against a 
complex of heparin and CXCL4 activate platelets. This could lead to a reduction of 
circulating platelet counts and is recognized as a risk factor for thromboembolic 
complications. The interaction between heparin and CXCL4 is not based on unspecific 
surface charges but on specific interactions between the positively charged amino acid 
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residues of CXCL4 (arginine, lysines at the C-terminal region) and the negatively charged 
sulfate group of the heparin polymer. CXCL4 mainly exists in solution as a tetramer 
(Mayo 1995). 
Along with a number of related (e.g. CXCL8) and unrelated chemokines (e.g. CXCL10)  it 
has been reported to inhibit proliferation of early committed hematopoietic progenitors at 
concentrations in the low nanomolar range in vitro (Dudek 2003). It is known that this 
cationic chemokine exhibits a strong antiangiogenic activity in vitro (Maione 1990) and in 
vivo (Hagedorn 2001). It suppresses growth of various tumors and metastases in vivo 
(Tanaka 1997). This effect is related to their antiangiogenic action and not to tumor cell 
proliferation (Bello 2002). Although CXCL4 is one of the first agents discovered to have 
an antiangiogenic action in ex vivo systems (Maione 1990), the specific receptor-related 
mechanisms that transduce the antiangiogenic signal of CXCL4 are still poorly understood. 
Recently it has been shown that CXCL4 binds also to integrins (αvβ3, αvβ5 and α5β1). 
This interaction had inhibitory as well as enhanced effects on integrin-dependend 
endothelial cell migration. Soluble CXCL4 mediated the inhibition of cell adhesion and 
migration, whereas immobilized CXCL4 promoted cell migration and sprouting (Aidoudi 
2008). 
Unlike virtually every other member of the chemokine family, a G protein-coupled 
receptor for CXCL4 analogous to the other well-defined CXC and CC chemokine 
receptors has yet to be characterized (Murdoch 2000). There has been a single report that 
CXCL4 binds to CXCR3B, an alternatively spliced product from the CXCR3 gene 
(Lasagni 2003). CXCR3B is 52 amino acid residues longer at its N-terminus compared 
with the previously recognized form, now termed CXCR3A. Unlike CXCR3A, which 
bound its agonists CXCL9, CXCL10, and CXCL11 exclusively, CXCR3B bound CXCL4 
as well. The high affinity of CXCL4 to CXCR3B with a Kd of about 4 nM, which was 
comparable to its other described ligands, suggested that CXCL4 may be a natural ligand 
for this receptor. Furthermore they showed that the activation of CXCR3A was Gαi protein 
coupled, which is pertussis toxin-sensitive and activates cellular proliferation, by contrast 
the activation of CXCR3B was carried out by bound Gαs protein, which was pertussis 
toxin-resistant and led to cellular apoptosis via formation of cAMP and activation of PKA. 
Nevertheless the biological relevance of this single observation is still not clear.  
It has been shown that CXCL4 mediates signaling via binding to the GAG chondroitin 
sulfate (Petersen 1998). Another study has shown that CXCL4 binds via GAG to the (low-
I  Introduction 
 12 
density lipoprotein) LDL receptor and disrupts the endocytosis of LDL, which results in 
retention on the cell surface (Sachais 2002). Also, CXCL4 mediates endothelial cell 
response and negative regulation of megakaryopoiesis via LDL receptor related protein 1 
(Lambert 2009). 
However, binding to biochemically and functionally different receptors may constitute the 
molecular basis for the heterogeneity of CXCL4 functions on various cell types. CXCL4 is 
therefore notable among the chemokines by virtue of its abundance, lack of potency to 
influence leukocyte function, and absence of a clearly defined high-affinity receptor. 
Platelets play an important role in thrombus formation. As CXCL4 is one of the most 
abundant proteins released during platelet plug formation, it exhibits both pro- and 
antithrombotic in vitro effects, depending on the context. Prothrombotic effects are exerted 
by binding to heparin and heparin-like molecules and thereby preventing the activation of 
antithrombin (AT) or by inhibiting the activation of FXII of the intrinsic pathway of 
thrombus formation (Sachais 2004). Recently, it has been reported that CXCL4 inhibits the 
anticoagulant function of activated protein C (APC) (Preston 2009). Contrary to that, the 
antithrombotic effect was shown by the enhancement of the activation of the activated 
protein C (APC) complex (Slungaard 2003). Here, CXCL4 binds and stimulates the 
cofactor activity of thrombomodulin (TM), an endothelial cell surface glycoprotein that 
binds thrombin and promotes the activation of protein C which restrains thrombin 
production and thrombus growth. The ability of CXCL4 to accelerate the activation of 
protein C by purified thrombomodulin (TM) is dependent on the presence of TM-
associated GAG (Dudek 1997). Mouse Cxcl4 knock out (Cxcl4 -/-) and human CXCL4 
overexpression in mice studies revealed no detectable phenotypes in steady-state. But in 
the ferric chloride (FeCl3) carotid artery injury model of thrombosis they showed a defect 
in the formation of occlusive thrombi compared with wild-type controls (Eslin 2004). 
Angiogenesis is another field where CXCL4 has an important role. CXCL4 was one of the 
first antiangiogenic agents discovered, inhibiting endothelial cell growth in vitro and 
preventing blood vessel proliferation in the chicken chorioallantoic membrane system in a 
dose dependent manner (Maione 1990). By binding to bFGF (basic fibroblast growth 
factor), CXCL4 inhibits their activating effect on endothelial cells. The mitogenic activity 
of bFGF requires interactions with both a high affinity receptor and a cell-surface heparan 
sulfate proteoglycan as co-receptor. The interaction with heparan sulfate and therefore the 
activity of bFGF is inhibited by CXCL4 (Watson 1994). This in turn inhibits its binding to 
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FGFR-1 (fibroblast growth factor receptor-1) and subsequent dimerization, which is 
responsible for receptor activation and internalization (Perollet 1998).  In the same manner 
the VEGF (vascular endothelial growth factor) activity is inhibited by CXCL4 (Jouan 
1999). The heparan sulfate proteoglycan-dependent binding of VEGF to its receptors 
VEGFR1-3 (Stuttfeld 2009), which belong to the platelet-derived growth factor tyrosine 
kinase family of receptors is blocked by CXCL4. The receptor binding of the shorter 
VEGF isoform with 121 residues, which lacks the heparin binding capacity, is not 
influenced by CXCL4 (Sachais 2004).  
Both of the above angiogenesis inhibitory systems are heparin dependent and require high 
concentrations of CXCL4 (~10 µM). This coincides with the reports that the lysine rich C-
terminus region of CXCL4 (residue 47-70) is involved in the interaction of heparin and 
heparin-binding proteins VEGF and bFGF (Ragona 2009). 
Multiple studies displayed the important role of platelet-derived chemokines in promoting 
atherosclerotic lesion formation. Chemokines (e.g. CXCL4, CCL5) from activated platelets 
are delivered to endothelial cell and leukocytes in the atherosclerotic plaques where they 
contribute to the exacerbation of atherosclerosis (Huo 2003). A study using carotid 
endarterectomy specimens from 132 consecutive patients with critical carotid stenosis 
revealed colocalization of CXCL4 with endothelial cell and plaque macrophages (Pitsilos 
2003). A causal role of CXCL4 in atherogenesis was also suggested by reduced lesion 
sizes in CXCL4-deficient Apoe-/- mice (Sachais 2007). One of the important insights of 
CXCL4 which could enhance atherosclerosis is its ability to bind the LDL (low-density 
lipoprotein) receptor via GAG which enables the inhibition of LDL binding. Also the LDL 
that bound in the presence of CXCL4 was neither rapidly internalized nor degraded, but 
remained in clusters on the cell surface that also contained the LDL receptor, a process that 
could promote the formation of oxidized LDL (ox-LDL) (Sachais 2002).  Furthermore, it 
was shown that CXCL4 could bind oxidized LDL (ox-LDL), but not native LDL, thereby 
promoting the binding of ox-LDL to endothelial cells, smooth muscle cells, and 
macrophages, and causing a ten fold increase in the esterification of ox-LDL (Nassar 
2003). 
Heterodimerization dramatically modulates the biological activities of these chemokines. 
For example, the formation of CXCL8-CXCL4-heterodimers increases the anti-
proliferative activity of CXCL4 against endothelial cells (Nesmelova 2005). The co-
presence of CXCL4 and CXCL8, in turn, attenuates the CXCL8-mediated rise in 
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intracellular calcium in a myeloid progenitor cell line and enhances CXCL8-induced 
migration of bone marrow-derived pro-B-cells (Baf/3) (Dudek 2003). 
It has been reported that CXCL4 homodimerization is electrostatically unfavorable because 
of the proximity of positively charged residues (histidine-35, lysine-46, lysine-61, lysine-
65, lysine-31) which oppose each other at the homodimer interface. In contrast to CXCL4, 
electrostatic interactions for CXCL8 homodimer formation are favorable. For 
CXCL4/CXCL8 heterodimer formation, there are significant changes in energetic 
contributions. Although heterodimerization for CXCL8 energetically, is unfavorable 
compared to homodimerization, due to the excess of CXCL4 concentration 
CXCL4/CXCL8 heterodimers are formed. These highly favorable associations drive 
CXCL4 tetramer to disrupt and more likely to form a heterodimer with CXCL8 
(Nesmelova 2008). 
 
I.6.2 CXCL4L1 
CXCL4L1 is a non-allelic variant of CXCL4 and a good feature of increasing the 
biological diversification of the human chemokine family by gene duplication. Unlike 
CXCL4, there has been no evidence of existence of murine orthologue, suggesting that the 
gene duplication occurred after the divergence of the two species (Eisman 1990). 
Although the gene had been cloned in the 1989/90 separately by 2 different groups and 
named PF4var1 (variant1) (Green 1989) and PF4alt (alternative) (Eisman 1990), the 
mature protein was isolated from thrombin-activated human platelets only recently by 
Struyf et al (2004). Like CXCL4 the human CXCL4L1 gene is located on chromosome 
4q13.3 (Zlotnik 2006). Compared with CXCL4, CXCL4L1 has 14% DNA and 38% amino 
acid divergence in the signal peptide region, and 2.6% DNA and 4.3% amino acid 
divergence in the coding region of the mature protein. 
The mature protein has, also a length of 70 amino acids but contains three amino acid 
substitutions (proline 58 ? leucine, lysine 66 ? glutamic acid and leucine 67 ? histidine) 
near the C-terminus. The latter two substitutions interrupt the alternating 
dibasic/dihydrophobic repeat found at the C-terminus of CXCL4, which is thought to be 
critical for high affinity binding to heparin-like molecules (Eisman 1990). 
CXCL4L1 compared with CXCL4 has been demonstrated to be a much stronger inhibitor 
of bFGF-induced endothelial cell chemotaxis (at least 10-fold) in vitro and more effective 
in blocking angiogenesis in vivo using the rat cornea micropocket assay (Struyf 2004). 
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These angiostatic effects, like CXCL4 were based on the inhibition of the angiogenic 
factors CXCL8 and bFGF. Further, using several animal tumor models it has been shown 
that the angiogenesis inhibition by CXCL4L1 leads to prevention of tumor metastasis 
development (Struyf 2007). 
Interestingly, CXCL4L1 has been found in other cell types and been shown to be secreted 
via alternative pathways (Lasagni 2007). Here, the authors showed that CXCL4 is 
predominantly expressed, stored and secreted by the regulated secretory pathway, whereas 
CXCL4L1 is synthesized continuously and secreted by the constitutive secretory pathway. 
Further, mRNA of CXCL4 appeared to be expressed more in almost all cells types 
(platelets, T cells, monocytes, endothelial cells) except in smooth muscle cells, where 
CXCL4L1 expression dominated. A possible reason could be the regulation and 
maintenance of vascular homeostasis and to avoid endothelial cell proliferation and 
aberrant angiogenesis. 
So far, no receptor for CXCL4L1 has been identified.  
 
I.6.3 CCL5  
CCL5 (regulated on activation, normal T cell expressed and secreted, RANTES) is a 7.852 
kDa and 68 amino acid long chemokine belonging to the β family. In search of T cell-
specific genes, the coding sequence of CCL5 had been found in a subtracted cDNA library 
isolated from a functional, antigen-stimulated T-cell line (Schall 1988). The gene coding 
for CCL5 was located on the chromosome 17q12 (Zlotnik 2006). It became apparent that 
CCL5 was not only expressed by T cells through the discovery of a protein with 
chemotactic activity present in the supernatant of thrombin-stimulated platelets which 
could be identified as CCL5 (Kameyoshi 1992). CCL5 was detected for the first time in the 
α-granules of human platelets by immunocytochemistry (Klinger 1995). Since then it 
became clear that many more cell types, such as fibroblasts, epithelial cells, and mesangial 
cells, express this pro-inflammatory molecule after activation with stimuli like IFN-γ and 
TNF-α. CCL5 is a potent chemoattractant for monocytes, T cells and eosinophilic 
granulocytes and beyond that exerts a less pleiotropic activity than CXCL4 (Schall 1990). 
The quaternary structure of CCL5 as a typical CC-chemokine is very different from that of 
the CXC chemokines since dimer formation occurs mainly at the mobile N-terminal 
regions, whereas CXC-dimers are assembled by the extension of their antiparallel beta-
sheet domains (Nesmelova 2005). 
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CCL5 binds to the G-protein coupled receptors CCR1, CCR3, CCR4 and CCR5. The first 
CC chemokine receptor cloned turned out to be the receptor for CCL5 (Neote 1993), and 
was designated CCR1 according to the receptor nomenclature system (Murphy 2000). 
Other receptors for CCL5 have been reported to be CCR3 and CCR4, which cause 
selective chemotaxis of eosinophils and basophils (Combadiere 1995). The last cloned 
chemokine receptor for CCL5 was designated CCR5 (Raport 1996). CCR1 and CCR5 
mediate differential functions, as CCL5-induced arrest of lymphocytes and monocytes is 
mediated by CCR1, whereas CCR5 is rather responsible for leukocyte transmigration 
(Weber 2001). 
Like CXCL4, CCL5 can also bind to GAGs. Here the interaction is based on the positively 
charged basic amino acid residues 44-47 in the first loop of CCL5 with the negatively 
charged sulfate group of heparin and exhibits a Kd of 32.1 nM (Martin 2001). Mutation of 
this region of CCL5 showed a decreased binding ability to heparin and a loss of 
chemotactic activity, which is induced via CCR1 (Proudfoot 2001). 
CCL5 deposition by activated platelets on atherosclerotic or inflamed endothelium triggers 
the arrest of monocytes (von Hundelshausen 2001). In addition CXCL4 enhances the 
monocyte arrest by forming heterodimers with CCL5 (von Hundelshausen 2005). 
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I.7 Aims of the study 
 
Platelets play an important role in the progression of atherosclerosis. It has been shown 
that platelet derived chemokines interact together and exacerbate lesion formation. CCL5 
induced monocyte arrest was enhanced by heterodimerization with CXCL4. Further for the 
non-allelic CXCL4 variant CXCL4L1, also present in platelets, a more angiostatic effect 
had been reported.  
To shed light into these interactions and to characterize the CXCL4L1 chemokine further, 
a strategy for the expression and purification of the platelet derived chemokines CCL5, 
CXCL4 and CXCL4L1 was developed. 
First, CCL5 was expressed in E. coli in LB and 15N-isotope enriched media purified by 
FLPC and the heterodimer formation with CXCL4 was investigated. 
Second, CXCL4 and CXCL4L1 were expressed in E. coli and purified using FPLC and 
HPLC methods. 
Further the CXCL4L1 was characterized by functional comparison with CXCL4. 
While CXCL4 has been intensively studied, its non-allelic variant CXCL4L1 has only 
been recently discovered and data of its function and structure are scarce. Therefore, the 
aim of this study was to characterize this protein with regard to its structural and functional 
properties. A strategy for protein generation had to be developed. Then the proper assays to 
investigate oligomerization, chemotactic and anti-angiogenic properties in comparison 
with CXCL4 were performed. 
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II Material and methods 
 
All solutions were prepared with Millipore water (Milli-Q Plus ultrapure purification, 
Millipore, Billerica, USA). Protocols were adapted from standard protocols (Sambrook 
2001) if not stated otherwise. All reagents were of analytical grade and purchased from 
major chemical suppliers such as Sigma-Aldrich (Steinheim, Germany), Carl Roth 
(Karlsruhe, Germany), Merck (Darmstadt, Germany) and Fluka (Buchs, Switzerland) 
unless otherwise stated in the text. 
 
II.1 General equipment 
 
autoclave Systec 2540EL (Systec, Wettenberg, Germany) 
balance Analytical Plus, (Ohaus, Pine Brook, USA) 
centrifuges Eppendorf 5417C (Eppendorf, Hamburg, Germany), 
Heraeus Labofuge 400 and Heraeus Multifuge 3 S-R 
(Heraeus, Osterode, Germany), Beckman Avanti J 30 I 
(Beckman Coulter, Krefeld, Germany) 
electroporator Gene-pulser II (Bio-Rad, Hercules, USA), Nucleofector 
device (Amaxa, Cologne, Germany) 
flow cytometers FACSCantoII (BD Biosciences, San Jose, CA, USA) 
fluorescence Microplate reader SpectraFluor Plus (Tecan, Crailsheim, 
Germany) 
LS 55 Fluorescence Spectrometer (PerkinElmer, USA) 
FPLC system Äkta FPLC ( Amersham/GE Healthcare, Uppsala, Sweden) 
gel electrophoresis Mini-sub cell GT (Bio-Rad, Hercules, USA) 
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HPLC system Spectra System SCM (Thermo Electron Corp., Thermo 
Scientific, Waltham, USA), Varion Prostar HPLC System 
(Varian Inc., Palo Alto,USA), Waters Delta Prep 3000 
HPLC System (Waters Corp., Milford, USA) 
image reader LAS 3000 (Fujifilm, Düsseldorf, Germany) 
incubator Innova 4230 (New Brunswick Scientific, USA) 
laminar flow hood Herasafe (Heraeus, Osterode, Germany) 
lyophilisator Alpha 2-4 LD plus (Christ, Osterode, Germany) 
microscopes Olympus IX71, IX50, IX51 (Olympus Optical, Hamburg, 
Germany) 
PCR thermocyclers MyCycler (Bio-Rad, Hercules,USA) 
pH-meter InoLab level 1 (WTW, Weilheim, Germany) 
sonicator Branson S-250 D Digital Sonifier (Branson, Danbury, USA) 
spectrophotometer GeneQuant (Amersham/GE Healthcare, Uppsala, Sweden), 
NanoDrop 1000 (PeqLab, Erlangen, Germany) 
 
 
II.2 Molecular biology 
II.2.1 General work with E. coli 
E. coli strains were cultured in LB medium at 37°C with vigorous shaking. For growth on 
solid media, a bacteria suspension was spread on a LB agar plate or a single bacteria 
colony was inoculated to achieve single colony growth. The LB plates were incubated 
inverted overnight at 37°C. For culturing of bacteria transformed with a plasmid conferring 
antibiotic resistance, growth medium was supplemented with the appropriate antibiotic. 
For long-term storage of bacteria at -80°C, LB medium containing the corresponding 
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antibiotics was supplemented with glycerol to a final concentration of 25% (v/v). All 
solutions used for bacteria work were autoclaved or filter-sterilized. 
 
Bacteria growth media 
Bacteria growth medium was autoclaved for 20 min at 121°C. LB agar medium was 
allowed to cool to 50°C before addition of antibiotics. 
 
LB medium: 0.5% (w/v) yeast extract 
 1% (w/v) peptone 
 1% (w/v) NaCl 
LB agar medium: LB medium with 1.4% (w/v) agar 
TB medium 1.2% (w/v) peptone 
 2.4% (w/v) yeast extract 
 0.4% (v/v) glycerol 
 
Preparation of heat-shock competent E. coli 
E. coli cells were inoculated in 5 mL LB medium and incubated overnight at 37°C with 
vigorous shaking. Then 100 mL LB medium were incubated with 750 µL of the overnight 
culture for 1 to 2 h at 37°C until the optical density at 600 nm (OD600) was approximately 
0.4, indicating the early exponential growth phase. OD600 was measured in a 
spectrophotometer with pure medium as reference. The culture was centrifuged (10 min/ 
3000 g/ 4°C), and the pellet was resuspended in 10 mL ice-cold TSS buffer. 500 µL 
aliquots were frozen immediately in liquid nitrogen and stored at -80°C. 
TSS buffer: 10% (w/v) polyethyleneglycol (PEG) 8000 (Promega) 
 5% (v/v) DMSO 
 20 mM MgCl2 
 in 1x LB medium (II.2.1)  
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Heat-shock transformation of competent E. coli 
100 µl thawed competent E. coli were gently mixed with 1-10 ng of plasmid DNA (see 
II.2.4.), and incubated for 30 min on ice. The bacteria were heat-shock treated for 45 sec in 
a 42°C water bath, and then incubated for 2 min on ice. After addition of 500 µL LB 
medium, the bacteria were incubated for 1 h at 37°C with gently shaking. The bacteria 
were spread on selective LB agar plates and incubated overnight at 37°C. 
 
II.2.2 Bacterial strains 
DH5α Invitrogen (Karlsruhe, Germany) 
XL1-Blue Stratagene (La Jolla, USA) 
Rosetta (DE3) pLysS Novagen/Merck Bioscience (Darmstadt, Germany) 
 
II.2.3 Plasmids 
pET-26+ expression vector containing pelB signal sequence for 
secretion of the recombinant protein into periplasma  
(Novagen/Merck Bioscience, Darmstadt, Germany) 
pET-26+/CXCL4 CXCL4 expression vector, this study 
pET-26+/CXCL4L1 CXCL4L1 expression vector, this study 
pET-32a expression vector containing a thioredoxin tag fused with  
the recombinant protein (Novagen/Merck, Darmstadt, 
Germany) 
pET-32a/CCL5 CCL5 expression vector, this study 
 
II.2.4 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify specific DNA sequences (Saiki 
1988). In addition, this method allows the introduction of new cleavage sites for restriction 
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endonucleases or other modifications (II.2.4) useful for the generation of DNA constructs. 
Primers with specific sequences were commercially synthesized (Eurofins MWG, 
Ebersberg, Germany). PCR fragments for cloning purposes were amplified with the high 
fidelity Pfu DNA Polymerase (Promega), which minimizes base misinsertions due to a 
3’→5’ exonuclease proofreading activity. Annealing temperature was optimized for each 
primer set based on the primer melting temperature. 
 
PCR reaction: 50-200 ng template DNA 
 1x PCR reaction buffer 
 0.5 μM forward primer 
 0.5 μM reverse primer 
 200 μM each of dNTPs (dATP, dCTP, dGTP, dTTP) 
 1.3 U DNA polymerase Pfu (Stratagene, La Jolla, 
USA) or Taq (Promega, Madison, USA) 
 H2O to final volume of 50 μl 
 
PCR program Initial denaturation 95°C, 1 min 
 Denaturation 95°C, 30 sec 
 Annealing 55-65°C, 30 sec 
 Extension  72°C 1-6 min 
 Final extension 72°C 5 min 
 
25-30 cycles 
 
II.2.5 Cloning of CXCL4 and CXCL4L1 
The coding region of the CXCL4 cDNA was obtained from ImaGenes (ID Hs.81564 
Berlin, Germany) and cloned downstream of the pelB signal sequence of the pET-26+ 
(Merck Biosciences, Darmstadt, Germany) expression vector by PCR (II.2.4) using 
specific primers: 
5’-GTG ATG ACG ACG ACA AGG AAG CTG AAG AAG ATG GGG ACC-3’ as 
forward primer and  
5’-ACT CGA GCA GCT AGT AGC TAA CTC TCC AAA AG-3’ as backward primer. 
The correct CXCL4 ligation in the expression vector was verified by restriction analysis 
and DNA sequencing (see II.2.11). This pET26+/CXCL4 expression vector served as a 
template to construct the pET26+/CXCL4L1 expressing vector by using the QuikChange® 
 22 
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Site-Directed Mutagenesis Kit (Stratagene, La Jolla, USA) to replace 3 amino acids 
(proline-58 to leucine, lysine-66 to glutamic acid and leucine-67 to histidine) at the C-
terminus end of the CXCL4. Following primers were used: 
5’-CAA GCC CTG CTG TAC AAG AAA ATC ATT AAG GAA CAT TTG GAG AGT 
TAG C-3’ as sense primer and 
5’- GCT AAC TCT CCA AAT GTT CCT TAA TGA TTT TCT TGT ACA GCA GGG 
CTT G-3’ as anti-sense primer. 
The protocol was performed according to the manufacturer’s instructions. The mutagenesis 
was verified by DNA sequencing (II.2.11) and both expression vectors were each 
transformed into E. coli Rosetta (DE3)-pLysS (Merck Biosciences, Darmstadt, Germany) 
as described in the section II.2.1. 
 
CXCL4 amino acid sequence 
EAEEDGDLQC LCVKTTSQVR PRHITSLEVI KAGPHCPTAQ LIATLKNGRK ICLDLQAPLY KKIIKKLLES 
 
CXCL4L1 amino acid sequence 
EAEEDGDLQC LCVKTTSQVR PRHITSLEVI KAGPHCPTAQ LIATLKNGRK ICLDLQALLY KKIIKEHLES 
 
II.2.6 Miniprep: Small-scale purification of plasmid DNA 
Plasmid DNA was purified from a bacteria culture by alkaline lysis as described 
(Sambrook 2001) mL over night (o.n.) culture was centrifuged (1 min/7000 g/rt) and the 
pellet was resuspended in 100 μL buffer 1. For lysis of the bacteria, 200 μL of buffer 2 was 
added followed by gently mixing and 5 min incubation at rt. The mixture was neutralized 
by 200 μL ice-cold buffer 3, gently mixed, and incubated for 5 min at -20°C. The 
suspension was spun down (20 min/20000 g/rt) to remove proteins, cell debris and 
chromosomal DNA. The supernatant with plasmid DNA was transferred to a new 
eppendorf tube mixed with 500 μL isopropanol and centrifuged (20 min/20000 g/rt). The 
pellet with plasmid DNA was washed with 70% (v/v) ethanol, air dried and resuspended in 
50 μL 10 mM Tris-HCl, pH 8.5.  
Buffer 1: 50 mM glucose 
 25 mM Tris-HCl, pH 8.0 
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 10 mM EDTA, pH 8.0  
 
Buffer 2: 200 mM NaOH 
 1% (w/v) SDS 
 
Buffer 3: 3 M potassium acetate, pH 5.5 
 
II.2.7 Midiprep and maxiprep: Large-scale purification of 
plasmid DNA 
Large-scale purification of plasmid DNA from bacteria on culture was performed using the 
Qiagen Plasmid Midi or Maxi Kit™ (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. 
 
II.2.8 Restriction endonuclease digestion of DNA 
Restriction endonucleases (MBI Fermentas, Ontario, Canada) were used to digest double-
stranded DNA for analytical purposes. Restriction endonucleases recognize specific 
palindromic sequences and cleave a phosphodiester bond at each strand at that sequence. 
Restriction endonuclease digestion of DNA for analytical purpose was done according to 
the manufactures instructions. 0.2-1 μg DNA were digested with 5-10 U of the restriction 
enzyme in a volume of 20 μL. Digests were incubated for 1 h at 37°C or as recommended 
by the supplier. Reaction buffers were supplied by the manufacturer. 
 
II.2.9 Agarose gel electrophoresis 
Separation of DNA fragments from digest was done by agarose gel electrophoresis. The 
negatively charged DNA fragments migrate towards the anode in an electric field at a rate 
determined by the size. DNA samples were diluted with DNA loading buffer and separated 
on a 1-2% (w/v) agarose gel dissolved in TAE electrophoresis buffer containing 0.1 μg/mL 
ethidium bromide. After electrophoresis at 120 V, the DNA was visualized on a UV light 
transilluminator and photographed for documentation. 
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DNA loading buffer (6x): 30% (v/v) glycerol 
 6 mM EDTA 
 0.25% (w/v) bromophenol blue 
 0.25% (w/v) xylenecyanol 
 
TAE electrophoresis buffer (1x): 40 mM Tris-acetate 
 1 mM EDTA 
 
II.2.10 Quantification of DNA 
DNA concentration was determined by measuring the absorbance at 260 nm (A260) in a 
spectrophotometer using a quartz cuvette or via NanoDrop ND-1000. For double-stranded 
DNA an A260 = 1 corresponds to 50 μg DNA/mL. The absorbance at 280 nm was also 
measured to estimate DNA purity. Pure DNA has an A260/A280 ratio of 1.8-2.0 at pH 7.0. 
 
II.2.11 Sequencing of DNA 
The sequence of DNA constructs were screened by a commercial sequencing service 
(Eurofins MWG, Ebersberg, Germany) and the sequence data were verified on the basis of 
the corresponding electropherogram. 
 
II.3 Protein analysis 
II.3.1 Protein concentration assay 
The DC Protein Assay (BioRad, Hercules, USA) was used to determine the protein 
concentration of the fractions. The method is similar to the Lowry Assay (Lowry 1951) 
and is based on the reaction of proteins with an alkaline copper tartrate solution and folin 
reagent. The measurement was done according to manufacturer’s instruction. Briefly, 5 µL 
of the fractions and BSA as standard were mixed with 25 µL copper tartrate solution and 
200 µL folin reagent. The complexation of the protein with copper tartrate and the 
following reduction of the folin reagent by the complex were measured at 750nm. 
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II.3.2 SDS-polyacrylamide gel electrophoresis (PAGE) 
After each purification step the fractions or fraction pools were analyzed by SDS-PAGE 
(Sodiumdocecylsulfate-polyacrylamide-gelelectrophoresis) (Laemmli 1970). SDS binds to 
polypeptides resulting in a negative charge directly proportional to protein size. Protein 
samples were first concentrated in a stacking gel before migrating into the resolving gel. 
Electrophoresis was carried out in a Mini-PROTEAN® 3 cell system (Bio-Rad, Hercules, 
USA) at 120 V until the bromphenol blue dye front reached the bottom of the gel. The 
resolving gel was analyzed either by coomassie blue, silver staining or western blotting 
(II.3.4-6). 
Resolving gel 12-15% (w/v) acrylamide/Bis 
 375 mM Tris-HCl, pH 8.8 
 0.1% (w/v) SDS 
 0.1% (w/v) ammonium persulfate 
 0.1% (v/v) TEMED 
  
Stacking gel: 5% (w/v) acrylamide/Bis 
 125 mM Tris-HCl, pH 6.8 
 0.1% (w/v) SDS (sodium-dodecylsulfate) 
 0.1% (w/v) ammonium persulfate 
 0.1% (v/v) TEMED 
  
Electrophoresis buffer: 250 mM Tris base 
 1.92 M glycine 
 1% (w/v) SDS 
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II.3.3 Tricine gel 
For a better resolution of the small proteins (<30kDa) a tricine gel electrophoresis was 
performed (Schagger 1987). Here the replacement of the tailing glycine ion by a faster 
tricine ion and the lower pH in the gel buffer results in a sharper band of the small 
chemokines. 
Resolving gel: 16.5% acrylamide/Bis solution 49.5%:3% 
 2.67 mL gel buffer 
 12.5% glycerol 
 0.1% (w/v) ammonium persulfate 
 0.1% (v/v) TEMED 
  
Stacking gel:  6% (w/v) acrylamide/Bis solution 49.5%:3% 
 1.65 mL gel buffer 
 0.1% (w/v) ammonium persulfate 
 0.1% (v/v) TEMED 
Gel buffer:  3.0 M Tris/HCl  pH 8.45 
 0.3% (w/v) SDS 
Cathode buffer (10x): 1 M Tris/HCl pH 8.25 
 1 M Tricine 
 1% SDS 
Anode buffer (10x): 2 M Tris/HCl pH 8.9 
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II.3.4 Coomassie blue staining 
The coomassie blue staining of the gels was carried out with PageBlue Protein Staining 
Solution (MBI Fermentas, Ontario, Canada). They were subsequently destained with a 
12.5% (v/v) isopropanol, 30% (v/v) EtOH. 
 
II.3.5 Silver staining 
Silver gel staining was adapted from Blum (Blum 1987). First of all, the proteins in the gel 
are fixed with solution A at least for 1 h. Then, after 3 x 20 sec washing (solution B) the 
gel was sensitized for 1 min (solution C). After that the gels were stained for 20 min with 
solution D containing AgNO3. Then the gels were treated with the developing solution E. 
At the end the reduction reaction is stopped with solution F. 
 
Solution A 50% methanol 
12% acetic acid 
0.05% formalin 
Solution B  50% methanol 
Solution C 0.02% (w/v) Na2S2O3 x 5 H2O 
Solution D 0.02% AgNO3
0.076% formalin 
Solution E 6% Na2CO3
0.0004% Na2S2O3 x 5 H2O 
0.05% formalin 
Solution F 50% methanol 
12% acetic acid 
 
II.3.6 Western blot analysis 
Separated proteins from a SDS-PAGE (II.3.2, II.3.3) were transferred to a nitrocellulose 
membrane and detected using specific primary antibodies and HRP-conjugated secondary 
antibodies. The proteins were transferred from the gel to the nitrocellulose Hybond 
membrane (Amersham/GE Healthcare, Uppsala, Sweden), at 90 V for 1 hour in ice-cold 
blotting buffer. Nonspecific binding sites on the membrane were blocked with 5% (w/v) 
nonfat milk in TBS for 1 hour at rt. Thereafter, the membrane was incubated with a 
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primary antibody diluted in blocking buffer for 1 hour at rt or overnight at 4°C. After 3 
times washing with TBS/0.05% (v/v) Tween, the membrane was incubated with a HRP-
conjugated secondary antibody diluted in TBS for 1 hour at rt or overnight at 4°C. In the 
presence of hydrogen peroxide (H2O2) the protein-bound HRP converts luminol to an 
excited intermediate dianion, which emits light on return to its ground state. This light can 
be captured by a detector (LAS 3000 Image Reader, Fujifilm, Düsseldorf, Germany). 
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Blotting buffer (1x) 25 mM Tris base
 192 mM glycine
 10% (v/v) methanol
 0.005% (w/v) SDS
 
 
 
 
TBS (1x) 25 mM Tris-HCl, pH 7.4
 2.7 mM KCl
 137 mM NaCl
 
II.3.7 Dot blot 
This technique was used to identify the presence of the proteins in the fractions purified by 
FPLC in a more rapid approach than a western blot. Fractions were spotted on a 
nitrocellulose membrane and after drying it was advanced like a western blot after blotting 
(II.3.6). 
 
II.3.8 Primary antibody 
  
CXCL4 anti-human-CXCL4 monoclonal antibody, clone 
MAB7951 (R&D Systems, Minneapolis, USA)  
CXCL4L1 anti-CXCL4L1 monoclonal antibody lacking Fc tail, 
AbD07088.1 (AbD Serotec, Martinsried, Germany)  
 AbD07089.1 
 AbD07090.1 
CXCL4L1-b AbD07088.1 biotinylated 
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 AbD07089.1 biotinylated 
 AbD07090.1 biotinylated 
CCL5 mouse Anti-Human Rantes VL1, RANT100 (Caltag, 
Burlingame, USA) 
CD11b-PE-Cy7 rat anti-mouse mAb, PE-Cy7-conjugated, DC and 
monocyte marker (clone M1/70, BD Pharmingen) 
CD45-APC-Cy7 rat anti-mouse mAb, APC-Cy7-conjugated, leukocyte 
marker (clone 30-F11, BD Pharmingen) 
CD115-PE rat anti-mouse mAb, PE conjugated, monocyte marker 
(clone AFS98, eBiosciences) 
F4/80-APC rat anti-mouse mAb, APC-conjugated, mature 
macrophage marker (clone A3-1, Serotec) 
Gr-1-PerCP rat anti-mouse mAb, PerCP-conjugated, mature 
granulocyte marker (clone RB6-8C5, BD Pharmingen) 
 
II.3.9 Secondary antibody 
goat-anti-mouse-IgG-
HRP 
horseradish peroxidase (HRP)-conjugated, sc-2031 
(Santa Cruz Biotech, Santa Cruz, USA) 
goat-anti-human-IgG-
F(ab')2 -HRP 
 
horseradish peroxidase (HRP)-conjugated anti-F(ab')2 
antibody, Code 0500-0099 (AbD Serotec, Martinsried, 
Germany) 
Streptavidine-HRP horseradish peroxidase (HRP)-conjugated, 016-030-084 
(Jackson ImmunoResearch, West Grove, USA) 
 
II.4 Protein expression and purification 
II.4.1 CCL5 expression and purification 
The CCL5 was expressed as inclusion bodies in the strain E. coli Rosetta (DE3)-pLysS 
using the pET32a+ vector (Novagen/ Merck Bioscience, Darmstadt, Germany). This vector 
permits the alignment of the desired protein as a fusion protein with thioredoxin, which 
facilitates the correct folding of the protein and enhances the formation of disulfides in the 
cytoplasm. The bacteria were grown either in LB or in Spectra-9N medium (Cambridge 
Isotope Labs, New Jersey, USA) containing 15N enriched isotope for better metabolic 
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labeling. In detail, the bacteria were transferred from an overnight plate to 2x 1L 
prewarmed medium (LB or Spectra-9N) containing 100 µg/mL carbenicillin as an 
ampicillin derivate and 40 µg/mL chloramphenicol. The bacteria were cultivated with 
shaking at 37°C. At an OD600 0.6 the CCL5 expression was induced overnight by 1mM 
IPTG (isopropyl-β-D-thiogalactopyranoside). 
The bacteria were harvested by centrifugation at 5000 rpm for 10 min. The pellet including 
the target protein as inclusion bodies was frozen at -20°C until usage. 
After thawing the pellet was resuspended in 5 mL/g wet cell weight BugBuster® Protein 
Extraction Reagent (Novagen/Merck Biosciences, Darmstadt, Germany) containing the 
Benzonase® nuclease. Additionally the mixture was sonicated at 50 W for 3x 30 sec until a 
homogenous lysate was formed. The inclusion bodies were washed 2x with PBS (PAA, 
Pasching, Austria) to remove membrane debris and detergents. Then the aggregated 
proteins were denatured in 6 M guanidine hydrochloride (Gnd-HCl) containing 1 mM DTT 
for about 1 h at 60°C or overnight at room temperature. After denaturation and 
disaggregation of the inclusion bodies, the protein was purified by several steps using the 
ÄKTA FPLC System (fast protein liquid chromatography).                                                         
 
II.4.2 CCL5 FPLC (fast protein liquid chromatography) 
Sephacryl S-100HR 
The first step of the CCL5 purification involved the gel filtration column Sephacryl S-
100HR (Amersham/GE Healtcare, Uppsala, Sweden). The denatured fusion proteins were 
loaded onto the column and separated according to their masses in 6 M Gnd-HCl, 50 mM 
Tris pH 8, 1 mM DTT. After verifying the presence of the CCL5/thioredoxin fusion 
protein in the collected samples (5 mL) by dot blotting, the next step was the refolding in 
6x diluted 50 mM Tris pH 8 in presence of 6 mM cysteine and 8 mM cystine as redox 
partners overnight at 4°C. Then the HiTrap chelating HP loaded with Ni2+ was used to 
purify the refolded fusion protein. 
 
HiTrap chelating HP  
The HiTrap chelating HP (Amersham/GE Healtcare, Uppsala, Sweden) column was loaded 
with Ni2+ as according the manufacturer’s instruction. Before loading the solution onto the 
column, the precipitations and other non soluble particles were removed by centrifugation 
(20.000g 30 min) and filtration (0.22 µm, Millipore, Billerica, USA). The protein was 
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loaded with binding buffer at 2 mL/min and eluted for 10 min with a linear 0-100 % 
gradient imidazole. 2-3 mL fractions were collected and all protein containing samples 
were pooled for the enterokinase digestion. The thioredoxin tag was removed from CCL5 
by digestion with 1 u per 50 µg enterokinase (Novagen/ Merck Bioscience, Darmstadt, 
Germany) overnight at rt. 
Binding buffer 20 mM Tris pH 8 
 2 M Urea 
Elution buffer 20 mM Tris pH 8 
 2 M Urea 
 250 mM Imidazole 
 
MonoS™ 5/50 GL  
After digestion, the CCL5 was separated from the thioredoxin tag by the strong cationic 
MonoS™ 5/50 GL column (Amersham/ GE Healthcare, Uppsala, Sweden). The CCL5 was 
eluted at 1 mL/min using a linear gradient from 0-50% elution buffer and collected at 0.5 
mL fractions. The correct size was verified by SDS-PAGE and dot blots. 
Binding buffer 50 mM NaAc pH 5.5 
 6 M Urea 
Elution buffer 50 mM NaAc pH 5.5 
 6 M Urea 
 2M NaCl 
 
Resource™ Reverse Phase Chromatography (RPC) 
In a last step of the FPLC the desired digested protein was further purified using the RPC 
(Amersham/GE Healthcare, Uppsala, Sweden). Here CCL5 bound to the polystyrene 
matrix of the column through hydrophobic interaction and almost all the impurities were 
removed. The elution was performed with a linear gradient from 0-67% at 1 mL/min. 
Again 0.5 mL fractions were collected and samples containing the correct protein were 
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analyzed by SDS-PAGE and western blot.  
Binding buffer 0.1% TFA (trifluoroacetic acid) 
Elution buffer 0.1% TFA (trifluoroacetic acid) 
 90% acetonitrile 
 
 
II.4.3 CCL5 HPLC (high performance liquid chromatography) 
At the end (polishing step) the recombinant CCL5 was purified by reversed phase-HPLC 
using a preparative Grace Vydac C-8 column (250 x 10 mm, 5 μm, Grace Davison 
Discovery Sciences, Deerfeald, USA). HPLC is a mode of chromatography that involves 
the separation of a protein via stationary and mobile phases. The stationary phase consists 
of porous beads containing several adsorbends (here C8 octyl group, non polar), and the 
mobile phase consists of a binary polar eluent mixture (buffer composition like RPC, sec). 
The binding between the protein and the C residues of the column is also based on the 
hydrophobic interaction. Following program was used: 
Time 
(min) 
Eluent 
A (%) 
Eluent 
B (%) 
Flow 
(mL/min)
0 100 0 1 
5 100 0 1 
35 33 67 1 
40 33 67 1 
43 0 100 1 
53 0 100 1 
56 100  1 
All collected peaks were frozen in liquid N2 and lyophilized. The samples were 
resuspended in H2O and the correct size was verified by coomassie blue staining and 
western blot. 
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II.4.4 CXCL4 and CXCL4L1 
The chemokines CXCL4 and CXCL4L1 were expressed in E. coli Rosetta (DE3)-pLysS 
periplasm in a modified hyperosmotic medium previously described by Barth (Barth 
2000). 
First the bacteria were grown in a preparatory 200 mL TB medium containing kanamycin 
(50 µg/mL), chloramphenicol (50 µg/mL) as antibiotics, ZnSO4 (0.5 µM) as protein 
stabilizer in the periplasm and 2% (w/v) glucose as carbon source at 26°C for 20 h. Then 
the bacteria were transferred in 2 L fresh TB medium as described above, except sorbitol 
(0.5 M) instead of glucose as carbon source, then 3% (w/v) NaCl as osmoticum, betaine 
(40 mM) and BMC (1,2-bis(2-mercaptoacetamido) cyclohexane) (10 µM) (Woycechowsky 
1999) as catalyzers, oxidized glutathione (2 mM) and reduced glutathione (1 mM) as redox 
additives. After acclimatization in the hyperosmotic medium for 1-2 h the protein 
expression was induced by 1 mM IPTG (isopropyl-β-D-thiogalactopyranoside) overnight 
at 26°C. Finally the cells were harvested and frozen at -20°C until protein purification. 
For the purification of the proteins, the cells were lysed in 5 mL/g cell pellet 5 mM MgSO4 
containing bacterial complete protease inhibitor cocktail tablets (Roche, Mannheim, 
Germany). After centrifugation for 30 min at 20.000g the supernatant containing the 
soluble protein was dialyzed against 50 mM NaAc pH 5.5 and the crude solution was 
purified by sequential steps using the ÄKTA FPLC System (fast protein liquid 
chromatography) and the HPLC (high performance liquid chromatography) Spectra 
System SCM. 
II.4.5 CXCL4 and CXCL4L1 FPLC 
HiLoad 16/10 SP-Sepharose™  
In a first step the cation exchanger column HiLoad 16/10 SP-Sepharose™ (Amersham/ GE 
Healthcare, Uppsala, Sweden) was used to remove undesired proteins and contaminants. 
The filtered (0.22 µm, Millipore, Billerica, USA) protein was loaded at a flow rate of 1-2 
mL/min, after about 15 mL of washing with binding buffer the protein was eluted with a 
linear gradient of 0-100% elution buffer for 20 min. Each fraction was collected in 5 mL. 
Binding buffer 50mM NaAc pH 5.5 
Elution buffer 50mM NaAc pH 5.5 
 2M NaCl 
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MonoS™ 5/50 GL or Capto™ S  
In a second step, the protein containing fractions, determined by dot blotting were pooled 
and the desired protein was dialyzed in the binding buffer of the next column prior to 
loading for further purification using the stronger cation exchanger MonoS™ 5/50 GL or 
Capto™ S (Amersham/ GE Healthcare, Uppsala, Sweden). Proteins were filtered again 
through a 0.22 µm filter to avoid clogging of the column by precipitates and loaded at the 
flow rate of 1 mL/min and eluted using a gradient 0-100% for 20 min. Each eluted sample 
was fractionated in 0.5 mL. 
Binding buffer 50mM NaAc pH 4.5 or pH 5 for Capto™S 
Elution buffer 50mM NaAc pH 4.5 or pH 5 for Capto™S 
 2M NaCl 
 
Resource™ RPC  
After verification of the fractions containing the correct protein by dot blot and SDS-
PAGE, the desired fractions were dialyzed 2 x against 1% acetic acid and 1 x against 0.1% 
TFA. Then in the third step the Resource™ RPC column was used. Here, proteins were 
bound to the column according to their hydrophobicity and elution was carried out with a 
linear increase of elution buffer containing the organic solvent acetonitrile in a 0-67 % 
gradient for 15 min. Each eluted sample was fractionated in 0.5 mL. 
Binding buffer 0.1% TFA (trifluoroacetic acid) 
Elution buffer 0.1% TFA (trifluoroacetic acid) 
 90% acetonitrile 
II.4.6 CXCL4 and CXCL4L1 HPLC 
In a final polishing step the reversed phase-HPLC was performed to purify and enrich the 
protein. HPLC is a mode of chromatography that involves separation techniques of a 
protein between stationary and mobile phases. The stationary phase consist of porous 
beads containing several adsorbents (here C18, octadecyl, non polar), and the mobile phase 
consists of a binary eluent mixture (here H2O and acetonitrile, polar). For this purpose 
Hypersil Gold column (Thermo Fisher, Waltham, USA) was used. This silica-based 
column provides C18 like selectivity for separation of hydrophobic as well as ionic 
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interaction. This dual character enables an excellent peak shape and therefore greater 
sensitivity. Following elutes for the binary mobile phase and gradient were used: 
Buffer  
Eluent A  0.1% TFA (trifluoroacetic acid) 
Eluent B 0.1% TFA (trifluoroacetic acid) 
 90% acetonitrile 
 
Program: 
Time 
(min) 
Eluent 
A (%) 
Eluent 
B (%) 
Flow 
(mL/min)
0 100 0 1 
5 100 0 1 
15 65 35 1 
25 65 35 1 
35 33 67 1 
45 33 67 1 
50 0 100 1 
55 0 100 1 
60 100 0 1 
 
II.4.7 Chemical synthesis of CXCL4L1 
Peptide synthesis and native chemical ligation 
The chemical synthesis of CXCL4L1 was carried out in the lab of Prof Tilman Hackeng 
(Department of Biochemistry, CARIM, Maastricht University) using the so called solid-
phase peptide synthesis (SPPS) method. SPPS was invented by R.B. Merrifield in 1963. 
Here the protein is manually polymerized beginning from the carboxyl terminus (C) of the 
amino acid to the amino terminus (N). First the C-terminal amino acid is attached 
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covalently via a linker to solid beads (resin), so that the growing peptide cannot be washed 
away during coupling steps. Then one side and the reactive side chains of the amino acids 
have to be protected to prevent self assembly or unwanted branched chains forming. 
Before assembly of the next amino acid, the N-terminus of the attached amino acid and the 
C-terminus of the joining amino acid have to be deprotected without affecting the side 
chain protection. After coupling of the second amino acid to the growing chain the next 
round of assembly can begin. There are two different groups of side chain protection, 
Fmoc and t-Boc. 
Fmoc stands for 9-Fluorenylmethoxycarbonyl and was introduced by R.C. Sheppard in 
1971. Under basic conditions this group is removed from a growing peptide chain (usually 
20% piperidine in DMF). Removal of side-chain protecting groups and peptide from the 
resin is achieved by incubating in TFA. 
t-Boc (or Boc) stands for tert-Butyloxycarbonyl. To remove t-Boc from a growing peptide 
chain, acidic conditions are used (usually TFA). Removal of side-chain protecting groups 
and the peptide from the resin at the end of the synthesis is achieved by incubating in 
hydrofluoric acid. For this reason the t-Boc method is generally disfavored. 
CXCL4L1 was synthesized by manual solid-phase peptide synthesis using the t-Boc 
method (Schnolzer 1992) and native chemical ligation (Dawson 1994). Since the SPPS 
method is limited up to a length of 40-60 residues and the mature CXCL4L1 has a length 
of 70 amino acids, the synthesis was carried out in two separate steps, N-terminal peptide 
(1-35 residues) on MPA-L-MBHA resin (mercaptoproprionic acid-leucine-
methylbenzhydrylamine, Penninsular Lab, Bellemont, USA) and C-terminal peptide (35-
70 residues) on MBHA resin (Fig.II.1). 
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Fig.II.1:  Strategy for the chemical synthesis of human CXCL4L1. (A) Amino acid sequence of 
hCXCL4L1 with the native chemical ligation site at His-35 and Cys-36. (B) Stepwise solid phase synthesis 
of the N-terminal and C-terminal peptides using the t-Boc method. The thioester group derived from MPA 
(mercaptoproprionic acid) is indicated in red.  
 
After that cleavage of both peptides form the resin by 10 mL HF (hydrofluoric acid) and 
deprotection of the side chains by 4% para-cresol were carried out. Then the peptides were 
purified by preparative HPLC (II.1) and lyophilized. The peptides were dissolved in 0.1% 
TFA at an end concentration of 20 mg/mL and the native chemical ligation was performed 
in presence of 10 µL/mL benzylmercaptan and 10 µL/mL thiophenol as catalyzers. The 
native chemical ligation is based on the chemoselective reaction between two unprotected 
peptides in which the C-terminal thioester undergoes a thiol exchange with the sulfhydryl 
side chain of the N-terminal cysteine. Thus after 24h incubation at 37°C a rapid, 
intramolecular rearrangement results in a native peptide bond at the site of the ligation 
(Fig.II.2). 
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Fig.II.2: Native chemical ligation of the two unprotected peptide segments results in a formation of an amide 
bond. The two segments are initially joined by thioester formation. COSR of the N-terminus undergoes 
nucleophilic attack by the side chain of Cys-36 of the C-terminus; subsequent spontaneous rapid 
rearrangement forms a native peptide bond at the ligation site. 
 
The final product was purified by preparative HPLC using a gradient from 0-100 % for 3 
h. Each peak collected was controlled by mass spectroscopy for the presence of the protein 
and lyophilized. Then the protein was refolded at a concentration of 0.1-0.2 mg/mL in 1 M 
Gnd-HCL pH 8 supplemented with 8 mM cysteine and 1 mM cystine for 24 h at 4°C. At 
the end the refolded protein was purified again by preparative HPLC. 
 
II.5 Biochemical analysis of the CCL5-CXCL4 heterodimer 
The biochemical analysis was performed in the lab of Dr. Kevin Mayo (Department of 
Biochemistry, University of Minnesota) and Prof Dr. Andreas Kungl (Department of 
Pharmaceutical Chemistry, University of Graz). The heterodimerization was characterized 
by the 15N-1H heteronuclear single quantum coherence (HSQC) nuclear magnetic 
resonance (NMR) method using 15N enriched CCL5. 
15N-CCL5 was dissolved at a concentration of 0.3 mM in 50 mM sodium phosphate buffer 
made using a 95% H2O/ 5% D2O mixture, and pH was adjusted to 3.4. This solution of 
CCL5 was mixed with CXCL4 chemokine. All NMR experiments were carried out at 40 
°C on a Varian Unity Inova 600-MHz spectrometer equipped with an H/C/N triple-
 39 
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resonance probe and x/y/z triple-axis pulse field gradient unit. A gradient sensitivity-
enhanced version of two-dimensional 1H-15N HSQC was applied with 256 (t1) × 2048 (t2) 
complex data points in nitrogen and proton dimensions, respectively. Raw data were 
converted, processed and analyzed by using NMRPipe and NMRview. The chemical-shift 
differences were averaged according to equation 1 and assignments were made based on 
those reported for CCL5 (Chung 1995; Duma 2007): 
δNH = ((Δδ (1H))2 + 0.25(Δδ(15N))2)1/2 
 
II.5.1 Molecular dynamics simulations 
The NMR or x-ray structures of CCL5 and CXCL4 were taken from the Protein Data 
Bank, (1RTO for CCL5 and 1RHP for CXCL4). Heterodimers were built by manually 
replacing one monomer subunit in a homodimer with a monomer subunit from another 
homodimer using Insight-II software (Biosym Technologies Inc., San Diego, CA). 
Molecular dynamics simulations were performed for homodimers of CCL5, CXCL4 and 
CC-type and CXC type heterodimers of CCL5/CXCL4 using the c29b2 version of 
CHARMM33. A one nanosecond trajectory was simulated for each hetero- and 
homodimer. All dimers were simulated in a 74 x 68 x 63 Å3 explicitly solvated periodic 
box. To make the box neutral, Cl- ions were added. Simulations were carried out using the 
version 22 all-hydrogen force field with a dielectric constant of 1.0. Each simulation was 
initialized with 2000 steps of steepest descent minimization, followed by gradual heating 
to 300 K and 5000 steps of system equilibration. The temperature during simulations was 
maintained at 300 K. 
 
II.5.2 Differential scanning calorimetry 
A high-sensitivity differential scanning calorimeter MicroCal VP-DSC (MicroCal, Inc., 
Northampton, USA) was used at a heating rate of 60 °C h–1. Cells were pressurized to 
about 28 psi to prevent loss of solvent by evaporation and the appearance of bubbles upon 
heating. Solvent buffer (PBS) was used to fill the reference cell and to obtain the 
instrumental baseline. Excess heat-capacity functions were obtained after baseline 
adjustment and normalization to protein concentration (CCL5-CXCL4 0.5 mg each). The 
heat capacity profiles were fitted applying a non-two-state model using MicroCal`s Origin 
software resulting in calorimetric (ΔHcal) and van`t Hoff (ΔHv) enthalpy values. 
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Temperature of protein unfolding (Tunfold) is taken as temperature of maximum heat 
capacity. Subsequent cooling and heating scans at 60°C h–1 were performed to gain 
information on the reversibility of protein unfolding. 
 
II.5.3 Interaction of CXCL4 or CXCL4L1 with CCL5 
Ligand blot 
1.5 µg of the respective chemokine was applied onto a Hybond nitrocellulose membrane 
and dried at room temperature and blocked with 3% non-fat milk in Tris-buffered saline. 
CXCL4 (1 µg/mL) binding reaction was performed in the same buffer, detected with the 
monoclonal anti-CXCL4 antibody and subsequent corresponding secondary antibody 
coupled to horseradish peroxidase and visualized with the Fujifilm LAS imager 3000. 
 
Isothermal fluorescence titration 
In the isothermal fluorescence titrations, emission spectra of 200 nM CCL5 solutions in 
PBS were recorded over a range of 300–400 nm at 100 nm/min. The maximum of 
excitation was determined at a wavelength of 282 nm (tryptophan at position 57). The 
ligand-induced fluorescence quenching was followed by adding aliquots of 50 nM until 
saturation was achieved. After each addition a period of 30 seconds was kept to allow the 
system to equilibrate by constantly stirring the solution. A coupled external water bath 
maintained the temperature in the samples during the measurements at 22 °C to ensure 
same conditions for all titrations. The slit widths were set at 5 nm and 10 nm for excitation 
and emission. Further a 290 nm cut-off filter was inserted in the emission path to avoid 
stray light. After background correction of the spectra the mean values of the fluorescence 
intensity (–ΔF/F0), were plotted against the volume corrected concentration of the 
respective ligands (CXCL4 or CXCL4L1). The resulting binding isotherms were analysed 
by nonlinear regression using the programme GraphPad Prism 4.0 to the equation 
describing a bimolecular association reaction: 
 
where Fi is the initial and Fmax is the maximum fluorescence value, Kd is the dissociation 
constant, and [CCL5] and [L] are the total concentrations of CCL5 and CXCL4 or 
CXCL4L1 ligand, respectively. The fitted parameters were Fmax and Kd. This equation is 
 41 
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based on the general solution for a bimolecular association reaction, as published (Goger 
2002). 
 
II.6 Cell culture 
II.6.1 General 
Cells were maintained in exponential growth in TS-25 or TS-75 (Greiner Bio-one, 
Frickenhausen, Germany) in a humidified 5% CO2 atmosphere incubator at 37°C. All 
media and solutions used for cell culture were from Gibco (Gibco/Invitrogen, Karlsruhe, 
Germany) or PAA (Pasching, Austria) if not stated otherwise and purchased sterile or 
sterilized through a 0.22 μm filter. The VenorGeM Mycoplasma detection kit™ (Minerva 
Biolabs, Berlin, Germany) was regulatory used for detection of any contamination of the 
cell lines with mycoplasmas. 
 
II.6.2 Cell lines 
The endothelial cell lines Human Umbilical Vein Endothelial Cells (HUVEC) and Human 
dermal microvascular endothelial cells (HDMEC) were purchased from PromoCell 
(Heidelberg, Germany) and were grown in Endothelial Cell Growth Medium and 
Endothelial Cell Growth Medium MV (PromoCell, Heidelberg, Germany) containing 50 
µg/mL gentamycine to avoid contamination with bacteria. The cells were used for 
experiments until passage number 6. 
The human monocytic cell line Mono Mac 6 (MM6) has been established from the 
peripheral blood of a patient with acute monocytic leukemia and was obtained from ATCC 
(Manassas, USA). MM6 cells were propagated in RPMI 1640 medium supplemented with 
10% (v/v) FCS, 0.1 U/l penicillin, 100 μg/mL streptomycin, 1x MEM non-essential amino 
acid solution, 9 µg/mL insulin, 1 mM oxalacetate and 1 mM pyruvate. Cells were 
maintained in 24-well plates at a density between 2 x 105 – 106 cells/mL. 
 
II.6.3 Culturing of adherent cell monolayers 
Adherent cell lines were grown until confluence and then passaged by using the cell 
detachment solution Accutase™. The monolayer was first washed with phosphate buffered 
saline (PBS) (PAA, Pasching, Austria) and then incubated 5-10 min with 0.25% (v/v) 
Accutase™ at 37°C. After detachment of the monolayer, Accutase™ was inactivated by 
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the addition of medium. For subculturing, cells were harvested by centrifugation (5 min, 
200 g, at room temperature) and then split with a ratio of 1:3. 
 
II.6.4 Culturing of cells in suspension 
Cells growing in suspension were cultured at a density of 105 - 106 cells/mL. Cells were 
harvested by centrifugation (5 min, 200 g, rt) and passaged with a ratio of 1:3-1:5. 
 
II.6.5 Freezing and thawing of cells 
Freeze stocks of cell lines were stored in 1.8 mL cryovials in liquid nitrogen. Cells were 
first harvested and then resuspended at a concentration of 106 - 107 cells/mL in complete 
medium containing 13% (v/v) dimethylsulfoxide (DMSO). The cryovials were placed 
overnight (o.n.) at -80°C in a cryocontainer to assure slow cooling and then transferred to 
liquid nitrogen for long-term storage. For thawing of cells, cryovials were rapidly thawed 
in a 37°C water bath. Cells were slowly added to 4 mL warm corresponding growth 
medium, centrifuged and resuspended again in growth medium. 
 
II.7 Functional assays 
II.7.1 Angiogenesis in vitro 
Tube formation assay was performed as previously described (Nicosia 1990). The matrigel 
(BD, Heidelberg, Germany) was diluted 1 to 3 with Endothelial Cell Growth Medium 
MV2 (Promocell, Heidelberg, Germany), transferred into a 24-well plate including 5 
µg/mL of each CXCL4 chemokine variant and allowed to solidify at 37°C. HDMECs 
(10.000/well) were plated in ECGF MV2 medium with or without 5 µg/mL of each 
CXCL4 chemokine. After 20 hours pictures were taken using an Olympius IX81 
microscope and tube formation was analyzed by the web based S.CORE Online Image 
Analysis software (S.CO LifeScience, Munich, Germany). 
 
II.7.2 Endothelial migration 
Transwell assay 
HDMECs were labeled with 1mM calcein-AM (Invitrogen, Karlsruhe, Germany) and 
seeded in 200 µL RPMI-1640 containing 1% HSA into the Falcon-HTS Fluoroblocks 
inserts (BD Falcon, Germany, 8.0 µm pore size) at a concentration of 1 x 105 cells/mL. 
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The inserts were placed in a 24-well plate with 300 µL RPMI-1640 and 1% HSA 
containing 300 ng/mL CXCL4 or CXCL4L1, or medium as control. After 3 hours the 
migrated cells were determined by measuring the fluorescence at 485 nm excitation and 
535 nm emission with the microplate reader (see section II.1). The same assay was also 
performed with different concentrations of CXCL4L1 (0; 50; 100; 300; 750 and 1500 
ng/mL).  
 
The µ-Slide Chemotaxis chamber 
The µ-Slide Chemotaxis chamber, purchased from ibidi GmbH (Munich, Germany), was 
used to distinguish between chemokinesis and chemotaxis. CXCL4 and CXCL4L1 were 
used at a concentration of 300 ng/mL. The assay was prepared according to the manuals of 
the company. Cell movement was observed with time-lapse microscopy at 37°C in a 30 
second interval for 3 hours using an inverted Olympus IX81 microscope. The data was 
analyzed with ‘Manual Tracking’ and ‘Chemotaxis and Migration Tool V1.01’ based on 
ImageJ (http://rsb.info.nih.gov/ij) as recommended by ibidi GmbH (Munich, Germany). 
 
Fig.II.3: µ-Slide Chemotaxis chamber. The μ-Slide Chemotaxis is a tool for observing chemotactical 
responses of migrating cells over extended periods of time. Two large reservoirs (40 μL) for medium are 
connected by a narrow observation area, where the cells are seeded. The chemoattractant is added into one of 
the reservoirs (red) and the cells in the observation area become super-imposed by a linear and time-stable 
gradient.  
 
II.7.3 Endothelial cell proliferation 
HDMECs (3.000 cells/well) were seeded in collagen-G coated 48-well plate with 
Endothelial Cell Basal Medium MV2 (PromoCell, Heidelberg, Germany) without and with 
10 µg/mL CXCL4 or CXCL4L1. After 0; 24; 48 and 72 hours the inhibition of the 
proliferation of the endothelial cells was determined using the CyQuant Cell Proliferation 
Kit Assay purchased from Invitrogen. The protocol was performed according to the 
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manual’s instructions and the data were normalized against the control. A dose-response 
curve was generated from 0-50 µg/ml chemokine and a time course established at 0; 24; 48 
and 72 hours. The inhibition of endothelial cell proliferation was calculated as follows: For 
time 0, medium was discarded and the plate frozen. Analysis was performed together with 
the plate containing cells after 72 hours of proliferation. A proliferation factor was 
calculated by dividing the actual fluorescence intensity by values obtained at time 0. The 
proliferation index was calculated by dividing the proliferation factor for medium alone by 
the value obtained for each chemokine concentration. Curves were fitted by non-linear 
regression analysis to determine the IC50 (GraphPad Prism 4.0). 
 
II.7.4 Monocyte recruitment 
In vitro 
A flow chamber adhesion assay was used to investigate cell arrest under physiological 
flow conditions. MM6 cells (105 cells/mL) were pretreated for 10 min with each of the 
chemokine CCL5, CXCL4, CXCL4L1, or in combination CCL5 + CXCL4, CC5 + 
CXCL4L1 (all 1 µg/mL) or only with PBS as control in 2 mL HH assay buffer (10 mM 
HEPES, 1x HBSS, 0.5% BSA) and 1 mM Ca2+/Mg2+. Then the monocytes were perfused 
at 1.5 dyne/cm over pre-activated (with 10 ng/mL IL β-1 for 6-12 hours) HDMECs. The 
number of monocytes firmly adherent by primary interaction with endothelium after 5 
minutes of accumulation was quantified in multiple fields by analysis of images recorded 
with a JVC 3CCD video camera and recorder (JVC, Yokohama, Japan). 
 
In vivo 
In vivo peritoneal recruitment of monocytes was determined in C57BL/6 (Charles River, 
Wilmington, USA) mice which were injected i.p. (intraperitoneal) with sterile PBS, 5 µg 
CCL5 alone or in conjunction with either 5 µg CXCL4 or CXCL4L1. After 4 h, the 
inflammatory infiltrate was harvested by intraperitoneal lavage with ice-cold HBSS 
containing 5 mM EDTA and stained with anti-CD45, -CD115, -Gr1, -F4/80 (eBiosciences, 
San Diego, USA), and analyzed by FACS. The absolute number was determined by 
CountBright absolute counting beads (Invitrogen, Karlsruhe, Germany). Inflammatory 
monocytes were determined as F4/80-, Gr1+ and CD115+ cells. 
 
II  Material and Methods 
 46 
II.7.5 Heparin neutralization 
For analyzing the binding and neutralizing the effect of heparin the activated partial 
thrombopoitin time (aPTT) test was conducted with and without CXCL4 or CXCL4L1. 
Pooled human plasma in Na citrate (Dunn Labortechnik, Germany) was mixed with the 
Dade® Actin® FS reagent (Dade-Behring, Germany) including 12 µU heparin (Ratiopharm, 
Germany) in presence and absence of various concentration of CXCL4 or CXCL4L1 (0; 1; 
2.5; 5; 7.5; 10; 15 µg/mL) and the aPTT was determined in a KC 10 coagulatometer 
(Amelung, Germany) according to the manufacturer’s instruction. 
 
II.7.6 Protein C activation 
Protein C activation by thrombin/thrombomodulin was measured as described (Slungaard 
1994). Rabbit thrombomodulin (5 nM) was preincubated with protein C (200 nM) and 
varying concentrations of recombinant CXCL4 or CXCL4L1 for 10 minutes at 37 °C in 
assay buffer (20 mM Tris pH 7.4, 100 mM NaCl, 0.1% BSA, 0.1% PEG-8000 and 0.1 mM 
CaCl2). Protein C activation was then initiated by the addition of 1 nM of thrombin and 
incubated for 30 minutes at 37 °C. The reaction was terminated by the addition of 100 nM 
hirudin, incubated for 5 minutes at 37 °C and APC amidolytic activity was measured at 
405 nm using S2366 in the microtiter plate reader at 37 °C. The amount of APC generated 
was calculated from a calibration curve using purified APC and S2366. A negligible 
amount of APC was formed in the absence of thrombomodulin. 
 
II.7.7 Data illustration and statistic analysis 
Graphs display results as mean ± SEM of 3 to 10 independent experiments, if not indicated 
otherwise. To compare data, one-way analysis of variance (ANOVA) and Newman-Keuls 
post-hoc test or an unpaired Student’s t-test with Welch’s correction was performed using 
GraphPad Prism 4.0. Differences with at least P<0.05 were considered as statistical 
significant. 
 
 
 
III  Results 
III Results 
III.1 Protein expression and purification 
III.1.1 Expression and purification of recombinant CCL5 
In order to characterization the interaction between CXCL4 and CCL5 and to develop a 3-
dimensional model by NMR (nuclear magnetic resonance)-spectroscopy one of the binding 
partners had to be labeled with the stable isotope 15N, which considerably increases the 
resolution and sensitivity of the NMR spectra. Hence CCL5 was expressed in E. coli as 
inclusion bodies in enriched 15N media as a fusion protein with thioredoxin. The inclusion 
bodies were purified from the bacterial lysate as described in section II.4.1. Then the pure 
inclusion bodies were denatured in 50 mM Tris pH 8 containing 6 M guanidine-HCl and 1 
mM DTT. 
The purification of 15N-CCL5 was carried out as described in Fig.III.1.1 in accordance 
with the following purification steps: Capture phase, Intermediate phase and Polishing 
phase. 
 
 
Fig.III.1.1: (A) Purification strategy of 15N-CCL5 and (B) the average yield of the protein after each 
purification step.  
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In the first FPLC purification step (capture phase), the solution was applied in 4 sequential 
steps onto the gel filtration column Sephacryl 200 HR (II.4.2). The column was run at a 
flow rate of 1 mL/min and 2.5 mL fractions were collected (Fig.III.1.2). The first 
opalescent fractions were discarded and the later fractions were pooled for refolding. 
The fusion proteins were refolded overnight at 4°C by a 6-fold dilution in a 50 mM Tris 
pH 8 buffer containing 6 mM cysteine and 8 mM cystine as redox additives.  
 
 
Fig.III.1.2: Gel filtration chromatogram of 15N-CCL5 using a Sephacryl S-200HR column. 15N-CCL5 
fusion protein was eluted in 4 successively steps with 6 M Guanidine-HCl; 50 mM Tris; pH 8; 1 mM DTT. 
5 mL fractions were collected and used for further purification. 
 
Since thioredoxin is able to bind Ni2+ ions, the next purification step (intermediate phase) 
was an IMAC (immobilized metal affinity chromatography) using HiTrap Ni2+ chelating 
columns (Fig. III.1.3). The refolded fusion protein was loaded in two steps (Run1 and 
Run2) onto the column and eluted with 250 mM imidazole (II.4.2). All eluted proteins 
were pooled and dialyzed against 20 mM Tris pH 8 overnight at 4°C. 
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Fig.III.1.3: FPLC chromatogram using the HiTrap Ni2+ chelating column.  In the second purification 
step a Ni 2+ chelating column was applied. As binding buffer 20 mM Tris pH 8; 2 M Urea was used. Bound 
proteins were eluted with the same buffer supplemented with 250 mM imidazole at 1mL/min. 2 mL fractions 
were collected and used for further purification. 
 
After buffer exchange the volume of the solution was decreased using the Macrosep® 
concentration tube. Subsequently a volume of 8-10 mL the thioredoxin tag was removed 
from 15N-CCL5 by digestion with enterokinase (1U/ 50 µg CCL5) for 16 hours at room 
temperature.  
Since the enzymatically liberated 15N-CCL5 formed an insoluble hetero-aggregate with the 
15N-CCL5/thioredoxin, the aggregate was pelleted by centrifugation for 30 min at 25 000 g 
and redissolved in a buffer containing 8 M Urea and 20 mM Tris pH 7.5. 
The separation 15N-CCL5 with thioredoxin was carried out by using the cation exchanger 
MonoS™ column (II.4.2, intermediate phase II). First the pH of the solution was decreased 
to 5.5 to avoid aggregation and to enhance binding of 15N-CCL5 onto the column. Then the 
solution was applied to the column previously equilibrated in 50 mM sodium acetate buffer 
pH 5.5 containing 6 M urea, which also supported the disaggregation. The absorbed 
protein was eluted with a linear 0-1 M NaCl gradient in the same buffer. The fractions 
containing only the cleaved CCL5 were pooled and dialyzed 2 x against acetic acid and 1 x 
against 0.1% TFA (Fig.III.1.4). 
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Fig.III.1.4: FPLC chromatogram using the Mono S™. After digestion of the fusion protein with 
enterokinase, pure 15N-CCL5 (fraction A14+A15, red rectangle) was separated from the fusion protein 
(fraction A10-A13) by Mono S™ column using 50 mM Na-acetate; pH 5.5, 6 M Urea as binding buffer and 
50 mM Na-acetate pH 5.5, 6M Urea, 2M NaCl as elution buffer. Flow rate was 1 mL/min and 0.5 mL 
fractions were collected. 
 
For the polishing step, the hydrophobic interaction chromatography (HIC) was performed 
using the reverse phase column Resource™ RPC (II.4.2). The dialyzed protein was loaded 
onto the column and bound protein was eluted with a linear 0-67% gradient using 0.1% 
TFA containing 90% acetonitrile. Each fraction was analyzed by SDS-PAGE and 
coomassie blue staining (Fig.III.1.5).  
 
 
Fig.III.1.5: FPLC RPC™ chromatogram. Fractions from Mono S™ containing 15N-CCL5 (A14+A15) 
were pooled and purified further by the RPC™ column in 3 successive runs. 0.1% TFA as binding buffer and 
0.1% TFA containing 90% acetonitrile as elution buffer were used to purify 15N-CCL5 from traces 
impurities. (bottom, right) All fractions were controlled for the presence of 15N-CCL5 (red rectangle, Run1 1, 
Run2 2+3) by SDS-PAGE (12.5% gel) and coomassie blue staining.  
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At the end of the purification procedure 5 µL aliquots from every of the purification steps 
were run on a 12.5% SDS polyacrylamide gel and analyzed either by coomassie blue 
staining (Fig.III.1.6 A) or by western blotting (Fig.III.1.6 B).  
 
Fig.III.1.6: Analysis of purification steps using SDS-PAGE after RPC™ purification. 5 µL aliquots of 
each purification step were loaded on a 12.5% acrylamide gel and stained with coomassie blue (A) or 
analyzed by western blot (B). (A) Coomassie staining: 1: CCL5 control, 2: SeeBlue® Plus2 marker, 3: before 
protein expression induction, 4: after induction, 5: Ni2+ pool, 6: supernatant of enterokinase digestion, 7+8: 
Macrosep concentration sample, 9: input Mono S™, 10+11: Mono S™ fusion protein fraction pool, 12: 
Mono S™ 15N-CCL5 fraction pool , 13 input RPC™, 14: pure 15N-CCL5 (red rectangle), 15: SeeBlue® 
Plus2 marker. (B) Western blot: 1: SeeBlue® Plus2 marker, 2: CCL5 control, 3: input RPC™, 4: pure 15N-
CCL5 pool (Run1 A14 + Run2 B5 and B4, red rectangle), 5: pool Run3 (B5+B4). 
 
 
III.2 NMR chemical shift mapping of CCL5-CXCL4 
heterodimer  
Since the cooperative effects of CXCL4 and CCL5 are explained by the direct interaction, 
we wanted to shed light on the structural basis of this interaction. The heterodimerization 
was characterized by the 15N-1H heteronuclear single quantum coherence (HSQC) nuclear 
magnetic resonance (NMR) technique in the lab of Dr. Kevin Mayo (Department of 
Biochemistry, University of Minnesota). Using this method, the chemical shift of the 
amino acids involved in the interaction of the monomers in comparison with the 
heteromers was measured. Titration of CXCL4 into a solution of uniformly labeled 15N-
CCL5 induced a chemical-shift change and a decrease in CCL5 monomer signal 
intensities, consistent with interactions of CCL5 and CXCL4 (Fig.III.2.1). Maximal 15N-1H 
chemical shift changes in the heteromer formation were observed in the N-terminal 
residues which indicated a CC-type rather than a CXC-type interaction. In the other hand, 
minimal chemical shift changes were found from residues of the first β-strand that 
mediates CXC-type dimer formation. 
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Fig.III.2.1: Biophysical characterization of CCL5-CXCL4 interaction. HSQC spectrum of 15N-CCL5 in 
the absence (gray cross-peaks) or presence (blue cross-peaks) of CXCL4 (molar ratio 1:1) with numbers 
representing respective CCL5 residues. Inset: Region from the HSQC spectrum of 15N-CCL5, exemplifying 
chemical shift changes caused by the addition of CXCL4 at the molar ratio of 1:16 (Koenen 2009). 
 
In support of the CC-type heterodimerization, molecular dynamics simulations on docked 
CC-type and CXC-type CCL5-CXCL4 heterodimers revealed a more thermodynamically 
favorable CC-type heterodimer conformation, as shown in the Fig.III.2.2 for the calculated 
free energies. 
 
Fig.III.2.2: Chemical shift perturbations analysis. Changes in chemical shift of 15N-CCL5 backbone 
amides in p.p.m. caused by the addition of CXCL4 (molar ratio, 1:2). Bottom, schematic of the secondary 
structure of CCL5; black boxes and the wavy line, β-strands and an α-helix, respectively (Koenen 2009). 
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Based on the molecular dynamics simulation a CCL5-CXCL4 heteromer structure could be 
calculated (Fig.III.2.3 A). There, the N-terminal CCL5 residues (3-6 aa) and the N-
terminal CXCL4 residues (7-10 aa) showed a close proximity. As shown by the chemical 
shift mapping these residues displayed the greatest chemical shift changes in the presence 
of CXCL4, particularly at high concentrations of CXCL4 (Fig.III.2.1 inset). Also the 
highly negatively charged remainder of the CXCL4 N-terminus crosses the net positively 
charged first and second loops of CCL5 (Fig.III.2.3 A), which is observed in the chemical 
shift changes within the first (21-24) and second (44-46) loop of CCL5 (Fig.III.2.2). In line 
with chemical shift changes observed in residues 60 and 62 the N-terminus of CXCL4 is 
proximal to the C-terminus helix of CCL5. Differential scanning calorimetry indicated that 
CCL5-CXCL4 heterodimers are stable at temperatures up to 65 °C (Fig.III.2.3 B).  
 
 
Fig.III.2.3: Structural model of the CCL5-CXCL4 heterodimer. (A) The most prominently involved 
residues are shown in red (CXCL4) and black (CCL5). The negatively charged N-terminus of CXCL4 
extends over the net positively charged first and second loops of CCL5. (B) Differential scanning calorimeter 
analysis of the heteromer. Solvent-normalized heat capacity curves as a function of temperature obtained by 
heating of CCL5-CXCL4 complex in PBS. Black and red curves represent two separate experiments with 
calculated melting temperatures of CCL5-CXCL4 of 76 °C (Koenen 2009). 
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III.3 CXCL4/CXCL4L1 Purification 
CXCL4 and CXCL4L1 were expressed in the periplasm of E. coli strain Rosetta DE3-
pLysS in TB medium and extracted from the bacteria as described in the section II.4.4. The 
recombinant proteins were separated from the bacterial lysate by centrifugation and 
purified sequentially using FPLC and HPLC step according to following purification steps: 
Capture phase, Intermediate phase, Polishing phase (Fig.III.3.1). In the following section, 
only the chromatographic purification steps of CXCL4L1 are described in detail, since for 
CXCL4, the purification procedure is identical. The correct size and the purity of the 
recombinant chemokines are summarized in Fig.III.3.6. 
 
 
Fig.III.3.1: (A) Purification strategy of CXCL4 and CXCL4L1 and (B) the average yield of the protein 
after each purification step. 
 
After dialysis of the bacterial periplasm solution against the binding buffer containing 50 
mM NaAc pH 5.5 the first purification step (capture phase) was performed by FPLC using 
the SP Sepharose™ column (II.4.5). Bound proteins were eluted at 0.6 M NaCl using a 
gradient between 0-2 M (Fig.III.3.2, Run1). The flow through was collected and loaded 
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again onto the column and eluted also with the same gradient as in Run 1 (Fig.III.3.2, 
Run2). Each fraction was controlled for the desired protein by dot blot analysis (II.3.7) 
(Fig.III.3.2, bottom). 
 
 
Fig.III.3.2: FPLC chromatograms of the first step of purification of CXCL4L1. Proteins were loaded on 
a HiLoad 16/10 SP-Sepharose™ column using 50 mM NaAc pH 5.5. Elution of bound protein was carried on 
with a 0-2 M NaCl gradient. The flow through of the first run was again loaded on the column and eluted 
using the same gradient (run2). (bottom left) All eluted fractions were controlled for the CXCL4L1 protein 
by a dot blot using specific antibodies against CXCL4L1 (see II.3.7). Fractions containing the protein (Run1: 
A4-A9, Run2: A4-A7) were pooled and used for further purification. (Same procedure was done with 
CXCL4, data not shown). 
 
After dialysis against 50 mM NaAc (pH 4.5 - 5) the protein was purified by the next FPLC 
step (intermediate phase) using a cation exchanger with a higher resolution capability (e.g. 
MonoS™ 5/50 GL or HiTrap CaptoS II.4.5). In both cases the bound protein was eluted 
with a linear 0-2 M NaCl gradient (Fig.III.3.3) and fractionized in 0.5 mL volumes.  Since 
Mono S has a lower binding capacity but a high resolution the flow through was loaded 
again for a better yield (Fig.III.3.3, Run 2). Each fraction was again controlled via dot blot 
analysis for the recombinant protein (Fig.III.3.3, bottom right). Fractions containing the 
protein were pooled and prepared for the next purification step by dialyzing 2 x against 1 
% acetic acid and 1 x against 0.1% TFA (trifluoroacetic acid) for at least 3 h.  
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Fig.III.3.3:  Purification of CXCL4L1 using Mono S™ or Capto™ S cation exchanger columns. For 
binding of the protein to the columns following buffer was used: 50 mM NaAc pH 4.5 (Mono S™, 
polystyrene-based matrix) or pH 5 (Capto™ S, agarose-based matrix). The elution was carried out with a 0-2 
M NaCl linear gradient. In the case of Mono S™ flow through from Run1 (FTRun1) was applied again onto 
the column (Run2). All fractions were collected and controlled for the desired protein by dot blotting. 
 
For the final removal of trace contaminants the reverse phase column RPC™ was chosen 
(polishing phase). The interaction of the protein with the resin of the column originated 
mainly through hydrophobic amino acid on the surface of the protein and the underivatized 
monodisperse polystyrene/ divinylbenzene beads. 
After dialysis against 0.1% TFA, the protein solution was loaded on the column with 1 
mL/ min flow rate and eluted with the organic solvent acetonitrile (90%) in 0.1% TFA 
using a 0-67% gradient (Fig.III.3.4). The eluted protein was collected in 0.5 mL fractions 
and the sizes were controlled by SDS-PAGE and coomassie staining (Fig.III.3.4, right). 
Fractions containing the correct size of the recombinant proteins were pooled and purified 
further by HPLC. 
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Fig.III.3.4: Reverse phase chromatography (RPC) of the CXCL4L1 protein. As a final purification step 
in the FPLC, proteins were loaded on a RPC column using 0.1% TFA as binding buffer and eluted using a 
linear 0-67% gradient with 0.1% TFA containing 90% acetonitrile (left). Fractions containing purified 
proteins (B8+B7, red rectangle) were analyzed by SDS-PAGE (12.5% gel) and coomassie staining (right). 
 
To obtain a highly pure yield, pooled protein fractions were applied on a HPLC system 
with a Hypersil Gold C-18 column. Using the program described in section (II.4.6), the 
pure protein was eluted with the elution buffer containing 0.1% TFA and 90% acetonitrile 
(Fig.III.3.5). All peaks obtained from the HPLC run were collected and lyophilized to 
remove the TFA and acetonitrile traces. The lyophilized proteins were dissolved in sterile 
H2O. The purity and correct sizes were analyzed by SDS-PAGE silver gel staining, 
western blotting and mass spectroscopy (Fig.III.3.6).   
 
 
Fig.III.3.5: HPLC chromatogram of CXCL4L1. Using the program described in section II.4.6, CXCL4L1 
was further purified from any other contaminants. Highly pure protein (see arrow, retention time: 21.5-23.5) 
was obtained and used for further characterizations.  
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Fig.III.3.6: Validation of the correct size and purity of CXCL4L1 and CXCL4. Silver gel staining 
following a SDS-PAGE and western blotting using polyclonal antibodies against CXCL4 and CXCL4L1 
were performed as reported in the section II.3.5 + 6 (Co: human CXCL4 form Chromatec (Greifswald, 
Germany), concentration of the proteins: 1 µg/mL). The correct masses were also determined by mass 
spectroscopy (7805.8 by electro spray ionization for CXCL4L1 and 7764.65 by MALDI TOF for CXCL4). 
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III.4 Chemical synthesis of CXCL4L1 
Solid-phase protein synthesis (SPPS) (Fig.III.4.1), invented by Bruce Merrifield in 1963, 
was used to synthesize CXCL4L1 in a more pure form compared to recombinant 
expression. 
 
 
Fig.III.4.1:  (A) Solid-phase protein synthesis (SPPS) strategy of CXCL4L1 and (B) the average yield of 
the protein after each purification step. 
 
As described in the section II.4.7 CXCL4L1 chemical synthesis was carried on in 2 steps. 
First the N-terminal segment of CXCL4L1 (1E-H35 aa) containing the thioester residue at 
position 35 was synthesized (yield: 811mg). Then the C-terminal segment (36C-S70 aa) with 
the important cysteine at the N-terminus was synthesized (yield: 832.2 mg). The synthesis 
was controlled by analytical HPLC and mass spectroscopy (Fig.III.4.2). 
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Fig.III.4.2: Total chemical synthesis of CXCL4L1 N-terminal and C-terminal segments. The 35-residue 
N-terminal peptide-thioester (COSR) fragment and the 35-residue C-terminal fragment of CXCL4L1 were 
synthesized by stepwise SPPS techniques using t-Boc chemistry protocols (II.4.7). The synthesis was 
monitored by analytic HPLC (A) (retention time of N-terminal segment at 20 min; retention time of C-
terminal segment at 24.5 min) and by mass spectroscopy (ESI-MS) (B). 
 
After cleavage of both segments from the resin and purification by preparative HPLC the 
yield resulted in 350 mg for crude N-terminal and 160 mg for crude C-terminal fragments. 
For the native chemical ligation 30 mg of each were used to assemble both segments for 24 
h at 37°C in presence of 1% benzylmercaptan and 1% thiophenol as catalyzers. In the 
native chemical ligation procedure, the thioester bond at the ligation site spontaneously 
rearranges and gives via an intramolecular nucleophilic attack a native backbone amide 
bond joining the two polypeptide segments at 35H-C36 (II.4.7, Fig.II.2). The progress of the 
ligation was monitored by analytical HPLC (Fig.III.4.3). The single segments gradually 
disappeared and a new signal emerged containing the full length protein.  The result was a 
complete native polypeptide chain that was obtained directly in its final sequence (dry 
yield after preparative HPLC: 12 mg). 
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Fig.III.4.3: Formation of CXCL4L1 by native chemical ligation. As shown by HPLC chromatograms, N-
terminal and C-terminal fragments were initially joined by thioester formation (as intermediate, t = 30 min), 
and a subsequent spontaneous, rapid rearrangement resulted in the formation of a native peptide bond at the 
site of ligation (at t = 4 h). Finally after 24 h ligation has been finished and pure protein was obtained after 
preparative HPLC purification (retention time at 23 min). 
 
Since the synthesized protein was reduced and not folded correctly, the protein was 
refolded at a concentration of 0.1-0.2 mg/mL in 1M guanidine HCl pH 8 containing 8 mM 
cysteine and 1 mM cystine as redox additives for 24 hours at 4°C. The refolding (final 
yield: 2 mg) was observed by HPLC as shown in the decrease of the retention time of the 
refolded protein compared with the unfolded ligation product (Fig.III.4.4) due to disulfide 
bond formations (cysteine-10 with cysteine-36, cysteine-12 with cysteine-52), and by mass 
spectroscopy (Fig.III.4.5). The sizes and the purity were verified also by silver gel staining 
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(Fig.III.4.6 A) following the SDS-PAGE or by western blotting (Fig.III.4.6 B). 
 
 
Fig.III.4.4: Folding and disulfide formation of CXCL4L1. HPLC chromatograms of the purified, reduced 
CXCL4L1 ligation product (top), the crude material after refolding (middle), and the purified final CXCL4L1 
product (bottom). 
 
 
Fig.III.4.5: Mass spectroscopy spectrums (MALDI TOF). Unfolded and folded CXCL4L1 with a 
calculated mass of 7807.77 and 7804.11 Da (theoretical mass of CXCL4L1: 7805). The decrease of the mass 
indicates the loss of the H atoms due to disulfide bond formations. 
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Fig.III.4.6: Validation of the purity of the chemically synthesized CXCL4L1. (A) SDS-PAGE silver gel 
staining showed the correct size of the synthesized protein (sCXCL4L1) compared to recombinant samples 
(rCXCL4L1). (B) The correct folding of the synthesized protein was also verified by a western blot using 
specific anti-CXCL4L1 antibodies. cont: CXCL4L1 control, synt: chemically synthesized CXCL4L1, rec: 
recombinant CXCL4L1. 
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III.5 Functional analysis of CXCL4L1 and CXCL4 
III.5.1 CXCL4L1 and CXCL4 inhibit tube formation 
Since CXCL4 had been well known for its angiostatic feature, we wanted to examine the 
effect of both CXCL4 variants in angiogenesis. We opted to assess the tube formation of 
microvascular endothelial cells (HDMEC) in matrigel as model. Matrigel was allowed to 
solidify with 5 µg/mL of the respective chemokine or medium alone before culturing 
HDMECs for 20 hours (II.7.1). Tube length was analyzed by the web based S.CORE 
Online Image Analysis software and indicated in micrometers. As reported in the literature 
(Struyf 2004), CXCL4L1 significantly reduced tube length  (Fig.III.5.1.1). On the other 
hand a difference between CXCL4L1 (142 µm) and CXCL4 (128 µm) with regards to the 
inhibition of endothelial tube formation could not be observed (control: 192 µm). 
 
 
Fig.III.5.1.1: CXCL4 and CXCL4L1 inhibit tube formation. (A) HDMEC were seeded on matrigel with 
or without the indicated recombinant chemokine and allowed to form tubes for 20 hours. Shown are 
representative microscopic images, where compared to the control (medium) CXCL4 and CXCL4L1 inhibit 
continuous tube formation. (B) Tube length was analyzed by the online analysis program S.CORE (control: 
192 µm, CXCL4: 128 µm, CXCL4L1: 142 µm). Statistical analysis was performed using the non-parametric 
Wilcoxon signed rank test (two-tailed; n = 5 independent experiments; * p<0.05). Images were recorded at 
100x magnification. 
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III.5.2 CXCL4L1 induces endothelial cell chemokinesis 
Given the angiostatic effects of CXCL4 and CXCL4L1, we investigated the capacity of 
both chemokines to affect endothelial cell migration. HDMECs were labeled with calcein, 
and seeded into the upper well of a chemotaxis chamber. The migration of endothelial cells 
was quantified by determining the fluorescence intensity below the surface. HDMEC dose 
dependently migrated towards a CXCL4L1 gradient. Interestingly, endothelial cells 
migrated to a comparable extent significantly and dose-dependently even when the 
gradient of CXCL4L1 was disturbed by the addition of equal concentrations to the upper 
well (Fig.III.5.2.1 A). On the other hand, CXCL4 elicited only weak endothelial cell 
migration when applied with or without a gradient which did not reach statistical 
significance (Fig.III.5.2.1 B). 
 
 
Fig.III.5.2.1: Effect of CXCL4L1 and CXCL4 on endothelial cell migration. Dose-dependent 
transmigration of calcein-labeled HDMEC with (empty bars) or without (filled bars) a gradient of 
recombinant CXCL4L1 (A) or CXCL4 (B) in combination with 20 ng/mL VEGF (C, D) or bFGF (E, F) was 
quantified by determining the fluorescence intensity in a modified Boyden chamber (Fluoroblok, Becton 
Dickinson) (n = 4-6 independent experiments, * p<0.05 compared to control by ANOVA and post hoc 
analysis with Tukey’s Multiple Comparison Test). 
 
Accordingly, cell migration distance obtained by time-lapse video microscopy of HDMEC 
in a µ-slide chemotaxis chamber (II.7.2) revealed that CXCL4L1 triggered the cells to 
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move a longer distance compared to CXCL4 (both 300ng/mL), which was significantly 
longer only compared to the control (Fig.III.5.2.2 A). Representative images of the 
migration paths of endothelial cells stimulated with the indicated chemokine or medium 
alone as control were selected (Fig.III.5.2.2 B). 
Fig.III.5.2.2: Time lapse microscopy. In a separate setup, the covered distance and direction were recorded 
online by video microscopy. (A) A stable gradient of CXCL4, CXCL4L1 or control medium alone was 
generated over firmly attached HDMEC in a µ-slide chemotaxis chamber and cell tracks were recorded by 
video microscopy. The migrated distance in µm was determined (n = 45 of 3 independent experiments). 
(B) Representative images of the migration pattern of HDEMC with the respective chemokine are shown (red 
lines indicate migration towards, black lines away from the stimulus). 
 
III.5.3 CXCL4L1 does not inhibit endothelial cell proliferation 
The presence of CXCL4 inhibits the proliferation of different cell types including 
endothelial cells. This prompted us to compare the potential of CXCL4L1 and CXCL4 to 
inhibit HDMEC proliferation. To rule out contaminations during the isolation of the 
recombinant chemokines, we also studied the effects of synthesized chemokines side-by-
side (II.4.7). Chemokines were added to HDMEC one hour after seeding to allow sufficient 
attachment, and proliferation was determined by analyzing the increase in DNA content 
using CyQuant® staining (II.7.3). Inhibition of cell proliferation was determined as percent 
inhibition compared to cells maintained in regular endothelial growth medium without 
chemokines. In general, no significant differences between recombinant and synthesized 
chemokines were observed. CXCL4 dose dependently inhibited endothelial cell 
proliferation (Fig.III.5.3.1 A). Using non-linear regression analysis, we calculated 
concentrations for half maximal inhibition of proliferation for recombinant (8.5 µg/mL), 
commercial-platelet-derived (6.9 µg/mL) and synthetic (6.7 µg/mL) CXCL4 (Table 2). In 
contrast to CXCL4, CXCL4L1 did not exert a measurable influence on the proliferation of 
endothelial cells. After 72 hours, recombinant CXCL4 at 10 µg/mL inhibited endothelial 
cell proliferation by 44% versus 0% for CXCL4L1 (Fig.III.5.3.1 B, Table 2). Both, 
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recombinant as well as synthesized CXCL4L1, were unable to block proliferation. 
 
Fig.III.5.3.1: CXCL4L1 and CXCL4 differentially affect endothelial cell proliferation. (A) The 
HDMEC number was quantified by CyQuant®. Chemokines were added at increasing doses and compared 
to medium alone. The proliferation index was calculated from the increase in fluorescence after 72 hours of 
proliferation for medium alone divided by the increase obtained with a given chemokine concentration; 
(ANOVA was performed for 50 µg/mL; n = 4 independent experiments; * p<0.05). (B) The time course was 
monitored for up to 72 hours with a constant chemokine concentration of 10 µg/mL (n = 4 independent 
experiments; ANOVA; * p<0.05). Chemokines were used either as recombinant (prefix r), synthetic (prefix 
s) or purified protein from platelet packs (prefix p) as indicated. 
 
 EC50  µg/mL Inhibition % 
pCXCL4 6.91 68 
rCXCL4 8.45 44 
sCXCL4 6.69 61 
rCXCL4L1 >70 0 
sCXCL4L1 >70 15 
 
Table 2: Inhibition of endothelial cell proliferation by chemokines. After non-linear regression analysis, 
the half-maximal effective inhibitory concentration (EC50) of CXCL4 and CXCL4L1 (prefixes: p = platelet-
derived, r = recombinant, s = synthetic) for inhibition of HDMEC proliferation was calculated, and the 
inhibition of HDMEC proliferation with indicated chemokines at a concentration of 10 µg/mL after 72 hours 
is given as percentage of control. 
 
III.5.4 Hetero- and homooligomerization differ in CXCL4L1 and 
CXCL4  
Since growth factors like bFGF and VEGF are the driving force for proliferation of 
endothelial cells and the inhibitory activity of CXCL4 on proliferation has been associated 
with direct binding of these factors, we semiquantitatively compared the interaction of 
VEGF, bFGF, and CCL5 using ligand blots (II.5.3). Incubation of CXCL4L1 with the 
immobilized proteins resulted in a measurable retention on immobilized VEGF, bFGF and 
CCL5, which was comparable to that of CXCL4 (Fig.III.5.4.1. A). Newly developed anti-
CXCL4L1 bivalent Fab-miniantibody (II.3.8) was used for specific detection of CXCL4L1 
(Fig.III.5.4.1. B). We also analyzed the affinity of CCL5 for CXCL4 and 
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CXCL4L1 by isothermal fluorescence titration (II.5.3) and observed a moderately reduced 
affinity of CXCL4L1 compared to CXCL4 (Fig.III.5.4.1. C). The titration of CXCL4L1, 
and CXCL4 respectively, into 200 nM CCL5 resulted in a significantly lower dissociation 
constant of 26 ± 1.2 nM for CXCL4 compared to 38 ± 8.8 nM for CXCL4L1. Thus a 
functional difference of CXCL4L1 may be explained by the reduced formation of pro-
adhesive CCL5 heterodimers. 
 
Fig.III.5.4.1: Heterooligomerization of CXCL4 and CXCL4L1. (A) CXCL4 or CXCL4L1 were incubated 
with immobilized VEGF, bFGF, and CCL5 (1.5 µg/spot). Direct binding was determined by incubating 
either CXCL4 or CXCL4L1 (1 µg/mL) and detection with anti-CXCL4L1 Fab-fragments and CXCL4 
antibodies (representative of 3 independent experiments). (B) Specificity of the CXCL4L1 Fab-fragments  
(0.5 µg/mL) is shown. (C) Fluorescence binding isotherms of the interaction of CCL5 with CXCL4 or 
CXCL4L1. The changes of endogenous fluorescence were plotted as the normalized fluorescence intensity 
changes (–ΔF/F0, where F0 is the initial fluorescence intensity). The dissociation constant Kd was derived 
from the isotherms which were fitted by non-linear regression (n = 4 CXCL4 and CXCL4L1, Mann-Whitney 
test, * p<0.05). 
 
Since distinct oligomer formation might explain differential functional characteristics, 
recombinant CXCL4 and CXCL4L1 were crosslinked or left untreated before being 
separated by SDS-PAGE under non-reducing conditions. Untreated chemokines showed a 
visible monomer, dimer and trimer band. Addition of the crosslinker DSS revealed the 
existence of tetramers and aggregate formation of both chemokines (Fig.III.5.4.2. A). Thus 
an apparent difference in oligomeric state of CXCL4L1 could not be observed. We 
subjected CXCL4 and CXCL4L1 to gel filtration in order to quantify the different 
oligomeric states more accurately (Fig.III.5.4.2. B). Compared to inert molecular weights 
standards, both CXCL4 and CXCL4L1 eluted at a later time point than expected. This 
might be explained by an interaction with the column hampering an unequivocal allocation 
of the peaks to tetramer, dimer or monomer state. After injection at 2 mg/ml, CXCL4 
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eluted in three peaks consisting of 73 %, 19 % and 8 % area under the curve (AUC) of the 
total peak area in line with the known distribution of predominantly tetramers. 
Interestingly, the elution profile of CXCL4L1 was composed of only two peaks (60 % and 
40 % of total protein), which eluted simultaneously with the putative CXCL4 dimers and 
monomers. 
 
Fig.III.5.4.2: Homooligomerization of CXCL4 and CXCL4L1. (A) CXCL4L1 and CXCL4 were 
crosslinked (DSS) or left untreated and separated by SDS-PAGE under non-reducing conditions 
(representative of 3 independent experiments). (B) Homooligomerization was quantified by gel filtration of 
CXCL4 and CXCL4L1 on a Super-SW 2000 TSK column (1 mg/mL in 500 mM NaCl, 0.2% Tween, pH 
7.0). The peaks of the putative tetramers, dimers and monomers are designated as T, D, and M. 
 
III.5.5 CXCL4L1 interaction with CCL5 does not enhance CCL5-
triggered monocyte arrest  
The functional relevance of the high-affinity interaction between CXCL4 and CCL5 has 
been shown previously (von Hundelshausen 2005). The formation of CCL5/CXCL4 
heteromers enhanced the recruitment ability of CCL5 for monocytes arrest into the 
vascular wall. Here, we wanted to know if CXCL4L1 attained the same effect. Monocytic 
Mono Mac 6 cells pre-incubated with CCL5 or its combination with CXCL4 or CXCL4L1 
were perfused on a monolayer of HUVECs. The coincubation of CCL5 with CXCL4 
resulted in a significant enhancement of firm monocyte arrest, whereas CXCL4L1 failed to 
increase CCL5-triggered monocyte adhesion significantly (Fig.III.5.5.1 A). 
These findings were supported by an in vivo assay demonstrating the robust recruitment of 
inflammatory monocytes into the peritoneal cavity after intraperitoneal injection of 5 µg of 
CCL5. Addition of 5 µg CXCL4 to CCL5 led to a further enhanced monocyte migration, 
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whereas injection of 5 µg CXCL4L1 instead of CXCL4 did not enhance CCL5-induced 
monocyte recruitment (Fig.III.5.5.1 B). 
 
 
Fig.III.5.5.1: Interaction of CXCL4 and CXCL4L1 with CCL5. (A) The arrest stimulating activity of 
CXCL4 and CXCL4L1 on CCL5 (all recombinant) activated monocytic Mono-Mac-6 cells was investigated 
under flow conditions. Cells were pulsed with the indicated chemokine (300 ng/mL) and the number of 
firmly adherent monocytes was determined after accumulation for 5 minutes. Data represent SEM of 4 
independent experiments (* p<0.05). (B) Monocyte recruitment in vivo. The ability of recombinant CCL5, 
CXCL4, and CXCL4L1 (5 µg) to recruit cells were tested by i.p. (intraperitoneal) injection. After 4 hours, 
the inflammatory infiltrate was harvested and monocytes were discriminated by the markers F4/80, Gr-1, and 
CD115 by flow cytometry (n = 5, * p<0.05 by Kruskal-Wallis test). 
 
III.5.6 Influence of CXCL4L1 on heparin neutralization and APC 
generation 
CXCL4 prevents inhibition of blood coagulation proteases by heparin at least in part 
independent of antithrombin by forming an inhibitory ternary heparin-fXa-CXCL4 
complex (Fiore 2009). The heparin-neutralizing activity of CXCL4 is well known and 
depends on positively charged amino acids, particularly lysine and arginine (Mayo 1995). 
We investigated differences in the heparin-neutralizing affinity by analyzing the aPTT 
(activated partial thromboplastin time, II.7.5) after adding heparin to pooled human normal 
plasma (Fig.III.5.6.1 A). In line with previous findings, the prolonged aPTT was reversed 
by adding CXCL4. Especially in the range of lower concentrations, CXCL4L1 less 
effectively neutralized the effect of heparin. The half-maximal concentration was achieved 
at 2 µg/mL of CXCL4L1 compared to 1 µg/mL of CXCL4. 
Conversely, heparin reverses the APC-generating activity of CXCL4 (Slungaard 1994). 
APC is a potent anticoagulant by proteolytically inactivating factors Va and VIIIa and is 
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generated in the presence of thrombin and thrombomodulin by proteolytic cleavage of 
protein C. As it has been reported, CXCL4 binds and induces conformational changes in 
protein C and enhances APC generation (Dudek 1997). We compared the capacity of 
CXCL4 and CXCL4L1 to generate APC (II.7.6). After incubation of protein C with its 
cofactor thrombomodulin and the chemokines, the reaction was started with thrombin, 
stopped with hirudin, APC concentrations were derived from the amidolytic activity 
relative to a calibration curve. Again, CXCL4L1 exhibited a less pronounced effect on 
APC generation, as compared to CXCL4 (Fig.III.5.6.1 B). 
 
 
Fig.III.5.6.1: Effects of CXCL4 and CXCL4L1 on heparin activity and APC generation. (A) Heparin 
activity  was measured by analyzing the activated partial thromboplastin time (aPTT) in heparinized pooled 
human plasma in the presence and absence of increasing concentrations of CXCL4 or CXCL4L1 (0 to 10 
µg/mL). The clotting time was normalized to the time measured in the absence of additional CXCL4 and 
CXLCL4L1 (n = 4). (B) The concentration of APC after thrombin stimulation of thrombomodulin and 
protein C was determined by measuring the absorbance after cleavage of the chromogenic substrate S2366  
(n = 4). Since the lower concentrations appear to overlap in the graph an inset is depicted to more clearly 
demonstrate the difference of the curves. 
 
 
 
 71 
IV  Discussion 
 72 
IV Discussion 
 
IV.1 Different expression strategies for obtaining the 
CCL5, CXCL4 and CXCL4L1 
For the characterization and comparative studies, the chemokines CCL5, CXCL4 and 
CXCL4L1 were recombinantly expressed in a bacterial system using E. coli (II.2.2) in LB 
or 15N-enriched medium (CCL5) and TB medium (CXLC4/CXCL4L1). Since these small 
proteins did not need any post-translational modifications, like e.g. glycosylation, the 
prokaryotic system seemed to be adequate. Two different approaches for the expression of 
these chemokines were used. CCL5 was expressed in the cytoplasm as inclusion bodies, 
whereas CXCL4 and CXCL4L1 were expressed as soluble, active proteins in the 
periplasm. For the expression of both chemokines the pET vector system (II.2.3) was used, 
where recombinant protein expression was under the control of the IPTG inducible T7lac 
promoter. Additionally the CXCL4L1 chemokine was also synthesized chemically using 
the solid phase peptide synthesis method (II.4.7). 
CCL5 fused with thioredoxin was expressed using the pET-32a vector system. Although it 
has been reported that the thioredoxin tag would be beneficial for obtaining highly soluble 
protein in the cytoplasm (LaVallie 1993), the main batch of the recombinant CCL5 was 
expressed as insoluble inclusion bodies. As a disadvantage, expression of proteins as 
inclusion bodies required a solubilization and refolding step in vitro to obtain the protein in 
an active conformation. Critical steps were the choice of solubilizing agents, e.g. 
guanidine-HCl, where a monomolecular dispersion was essential and also the conditions 
for the refolding of the protein, where parameters like pH, presence of redox reagents, the 
speed of denaturant removal were important. Nevertheless inclusion bodies harbored also 
some advantages, e.g. they were easily isolated by centrifugation to yield highly 
concentrated homogenous protein and also proteolytic attacks were diminished by 
formation of inclusion bodies. 
Although expression of recombinant protein as inclusion bodies included some additional 
effort, the received yield of fully active recombinant CCL5 was satisfactory for further 
characterization of CCL5. Furthermore, by incubating the expressing bacteria in 15N-
enriched medium, it was possible to produce recombinant 15N-CCL5, which enabled an 
increased resolution in the structural determination of the heterodimerization of CCL5 with 
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CXCL4 (III.2).  
For the expression of CXCL4 and CXCL4L1 the pET-26+ vector was chosen. The 
expression product of this vector was transported in the periplasmic space under 
hyperosmotic condition supplemented with compatible solutes such as betaine or glycerol 
(III.3). The pelB signal sequence of the pET-26+ vector allowed the secretion of the 
recombinant protein into the periplasm, where the pelB signal sequence was cleaved off 
from the recombinant protein by the bacterial enzymes at the cytoplasmic membrane 
resulting in an active protein without any additional tags. The periplasmic space with its 
oxidizing milieu (Bardwell 1993) also supported the disulfide bond formation and 
therefore the correct folding of the recombinant protein. 
As already described for the expression of the immunotoxin in the periplasmic space 
(Barth 2000), low temperature (20-26°C), hyperosmotic conditions (4% NaCl) and at the 
same time protection of the recombinant proteins by compatible solubles (or osmolytes) 
supported formation of highly pure and correctly folded protein, although the yield was 
low. Beside the low yield the most challenging factor was the ineffective cleavage of the 
pelB signal sequence from the recombinant protein. A reason for this could be the overall 
positive net charge of the CXCL4 and CXCL4L1, since it has been reported that 
hydrophobic and positively charged amino acid residues can block the export of proteins 
into the periplasmic space when introduced after the pelB signal sequence (Kajava 2000).  
Nevertheless the compatible solute-supported periplasmic expression offered an alternative 
method for expression of soluble, active and correctly folded recombinant proteins, 
without involving an in vitro refolding step. 
As already mentioned, CXCL4L1 was also synthesized chemically by the SPPS method to 
obtain highly purified protein. Since the SPPS method is limited to 40-60 amino acid 
residues, the CXCL4L1 was synthesized in two peptide parts (N-terminal and C-terminal) 
and assembled by native chemical ligation (Fig.II.2). The synthesis of each peptide part 
started with the C-terminal amino acid and ended with the N-terminal amino acid 
(Fig.II.1), where the amino acids were connected sequentially step-by-step. To prevent a 
misfolding and undesired polymerization the side chains of the growing polypeptide were 
protected by a t-Boc group. Removal of the protecting group and the peptide from the resin 
was achieved by treatment with the highly toxic HF (hydrofluoric acid). The ligation of the 
unprotected peptide segments was performed as described in section II.4.7 which resulted 
in a fully functional active CXCL4L1. The correct formation of the disulfide bonds was 
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also proven by a shortened retention time of the folded CXCL4L1 compared to the 
unfolded extended byproducts by RP-HPLC (Fig.III.4.4), because of the more polar 
surface area. The refolding was also demonstrated by ESI-MS, where a shift from a higher 
m/z state (unfold) to a lower m/z state (folded) was observed (Fig.III.4.5), due to less 
potential residues for carrying a charge on native, folded proteins under ESI-MS ionization 
conditions compared to unfolded. 
Taken together, synthesizing CXCL4L1 by the SPPS method resulted in the generation of 
highly pure protein with a higher yield compared to recombinant techniques. 
 
IV.2 Structural differences between CXCL4 and CXCL4L1 
The amino acid changes in mature CXCL4L1 (proline-58 to leucine, lysine-66 to glutamic 
acid, leucine-67 to histidine) may cause significant alterations in the secondary structure of 
the protein. All three residues are conserved in human (Walz 1977), rat (Doi 1987), and 
bovine (Ciaglowski 1981) CXCL4. Therefore, the differences in CXCL4L1 are not likely 
caused by CXCL4 gene duplication. The proline-58 to leucine change could have a major 
effect on the secondary structure of the protein because the carboxy-terminal helix of 
CXCL4 starts at proline-58. Since proline is a helix breaker, the change to leucine could 
extend the helix in the amino-terminal direction and alter the turn at positions 55 to 57 that 
links the helix to the third strand of the β-sheet. Due to the lysine-66 to glutamic acid 
change, the carboxy-terminal region of CXCL4L1 would be less positively charged than 
that of CXCL4, which could also explain the reduced interaction with the anionic heparin. 
The leucine-67 to histidine change could also significantly alter the characteristics of the 
carboxy-terminal helix. Leucine-67, which is between the helix and the hydrophobic 
surface of the β-sheet, is buried and surrounded by hydrophobic residues. Histidine at this 
position, especially if it is protonated, would weaken the packing of the helix against the 
sheet (Green 1989). 
The leader sequence of the CXCL4L1 gene showed the greatest change from that of 
CXCL4. Albeit only 15 of the 93 nucleotides were different, except for a three-codon 
insert in the middle of the sequence. However, these differences resulted in an increased 
net positive charge of the CXCL4L1 leader sequence resulting from five arginine residues 
compared with only one for CXCL4. This may imply a difference in the tissue or cell type 
in which CXCL4L1 is expressed or a difference in its mode of secretion (Lasagni 2007). 
Interestingly CXCL4 in combination with CXCL8, which is also present in platelets, 
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showed an inhibitory effect by blocking CXCL8 mediated activation of hematopoietic 
stem cells (Dudek 2003) and increased anti-proliferative effects from CXCL4 on 
endothelial cells in culture (Nesmelova 2005).  
The conserved monomer structure of all of the CXC and CC chemokines generally allows 
heterodimerization. The interaction of specific pairs of amino acid residues at the dimer 
interface of individual monomers seems to dictate the nature of thermodynamic stability 
and selection of dimer type (CXC or CC). This applies especially for CXC-CC mixed 
heterodimers, where placement of specific amino acid residues (positively/ negatively 
charged, polar, or hydrophobic) within the β-strand 1 and/or within the N-terminus 
determines selection of CXC-type or CC-type heterodimers. It has been shown that for 
CXCL4 the homodimerization is thermodynamically unfavorable because of the repulsion 
of the positively charged amino acids at their dimerization site, whereas in a tetramer 
formation these amino acids do not repel each other. Moreover, in a CXCL4-CXCL8 
interaction, CXCL8 is responsible for the dissociation of the CXCL4 tetramer and supports 
the formation of CXCL4-CXCL8 heterodimers. In general, heterodimerization is mediated 
primarily by non-electrostatic interactions, with the exception of CXCL8 and CCL5 where 
electrostatic forces contribute significantly to the binding free energy (Nesmelova 2008). 
 
IV.3 CXCL4-CXCL4L1 functional comparison 
Platelets play a crucial role in the manifestation of atherosclerosis. They either act directly 
by rolling and adhering to the endothelial cells or indirectly by releasing stimulatory 
mediators (e.g. chemokines). Upon activation, platelets secrete chemokines from their α-
granules, which are deposed onto endothelial cells and participate in the progression of 
atherosclerosis. It has been shown that injection of activated platelets in ApoE-/- mice 
exacerbates atherosclerotic lesion formation and delivers chemokines, such as CCL5 and 
CXCL4 onto atherosclerotic endothelium led to an increased monocyte arrest recruitment 
and followed by transmigration of the endothelium (Huo 2003). 
In chronic inflammatory processes such as atherosclerosis, CXCL4 plays a proatherogenic 
role which is not yet fully understood (von Hundelshausen 2007). A potential mechanism 
resides in its enhancing effects on the subintimal recruitment of monocytes by CCL5. It 
has been shown that CCL5-induced monocyte arrest can be enhanced by high-affinity 
interaction with CXCL4, which has a considerable impact on the development of 
atherosclerotic lesions in the mouse. Moreover, using pulsed field gradient NMR self-
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diffusion experiments demonstrated that CCL5 induced dissociation of CXCL4 tetramers, 
which were normally formed in solution (Mayo 1989; Koenen 2009) and promoted 
formation of CCL5-CXCL4 heterodimers in a CC-type configuration. Furthermore, this 
synergistic enhancement of the monocyte-recruiting function of CCL5 could be blocked by 
peptides disrupting the interaction of CXCL4 and CCL5, which expanded the therapeutic 
potential of anti-atherosclerotic treatment. A synthetic cyclic peptide, named CKEY2, 
based on CCL5 residues 24-44 (β1 and β2 strands), competed with CXCL4 for binding to 
the N-terminus of CCL5 (Kd = 100 nM). Through introduction of the murine peptide 
orthologue, MKEY, into hyperlipedemic mice on high fat diet, the inhibition of the 
enhancement of CCL5-induced monocyte arrest by CXCL4 was verified also in vivo. The 
progression of atherosclerosis and the monocyte accumulation in the plaque were 
significantly reduced compared to a scrambled control peptide. Unlike the treatment with 
the CCL5 antagonist Met-CCL5, where the T-cell proliferation and the virus clearance 
were impaired (Sorensen 2004), immunological side effects and hampered normal CCL5-
related survival signals had not been observed by treatment with MKEY (Koenen 2009). 
Other than CXCL4, CXCL4L1 failed to enhance CCL5 induced monocyte arrest which 
might be explained by the reduced affinity to CCL5. Nevertheless the substitutions of the 3 
amino acids in the C-terminal helix of CXCL4L1 seem to influence the structure of the 
protein at such rate that different physiological effects occur. The remaining affinity of 
CXCL4L1 to CCL5 is probably due to the N-terminal interaction as observed for the CC-
type of the CXCL4-CCL5 heterodimer.  
In the course of evolution, a possible duplication of the CXCL4 gene might have occurred 
quite recently, because an orthologue gene sequence was not identified in the mouse 
genome (Eisman 1990). The absence of the CXCL4L1 gene in rodents suggests that it may 
not have a critical role in platelet function. Nevertheless it has been reported that 
CXCL4L1 in humans exerts a more effective angiostatic activity than CXCL4. 
Since a direct comparison of CXCL4 and CXCL4L1 has not yet been performed so far, we 
were prompted to uncover biological differences between these proteins, which might lead 
to a better understanding of their role in the physiology and pathophysiology of blood and 
vascular diseases. Although exact mechanisms are not yet fully elucidated, CXCL4 and 
CXCL4L1 both exert angiostatic effects (Struyf 2004). Angiogenesis is a finely regulated 
process requiring multiple stimulatory and inhibitory molecular cues and is dependent on 
both, the proliferation and/or the recruitment/migration of endothelial or endothelial 
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progenitor cells and their correct assembly (Carmeliet 2005). Thus, the directed migration 
of endothelial cells is crucial for the development of a prevascular structure. Relevant 
chemotactic properties for different leukocyte populations, which have initially been 
ascribed to CXCL4 in the 1980s, could not be reproduced and might therefore have been 
due to concomitantly isolated chemokines during protein purification from platelets. 
However, recent findings indicate chemotactic properties of CXCL4 in activated T cells 
(Mueller 2008). Our finding that endothelial cell migration is rather weakly induced by 
CXCL4 and much more potently induced by CXCL4L1 in a transwell-filter assay is only at 
first sight contradictory to findings by Struyf et al., who found CXCL4L1 to be a potent 
inhibitor of bFGF- and CXCL8-mediated endothelial cell migration in a similar 
chemotaxis assay. The migration pattern of endothelial cells in the µ-slide chamber, which 
permits analyzing the direction and length of the covered distance, reveals that CXCL4L1 
primarily stimulates endothelial cell motility and increases migration length but does not 
influence the direction of cell movement. These experiments as well as checker-board 
analysis indicate that CXCL4L1 induces random migration that lacks directionality 
(chemokinesis) rather than enhanced-rate locomotion with a gradient-imposed, 
unidirectional migration (chemotaxis) of endothelial cells. Of note VEGFA, a highly 
potent angiogenic factor elicits chemotaxis and simultaneously reduces chemokinesis 
emphasizing the importance of the directed endothelial migration for angiogenesis 
(Barkefors 2008). Our experiments confirm these observations, since both VEGF and 
bFGF were chemotactic yet able to block CXCL4L1 induced chemokinesis. Although 
endothelial cells in culture are adjusted to similar conditions such as growth factor 
supplement and lack of shear stress, their provenience leaves site-specific properties which 
are epigenetically programmed (Aird 2007). Thus, for instance microvascular endothelial 
cells of dermal or pulmonary origin may deviate in their phenotype which may lead to 
differences in experimental results. The angiostatic mechanism of CXCL4 has been 
proposed to depend on specific inhibition or competition of growth factor-stimulated 
endothelial cell proliferation e.g. bFGF and VEGF (Maione 1990; Gengrinovitch 1995). 
The effects of CXCL4L1 on undirected endothelial migration may be also mediated by a 
replacement of other growth factors or by direct activation of CXCR3 and thus, may 
provide an alternative explanation for angiostatic effects. 
In line with these results, CXCL4 inhibited endothelial cell proliferation, whereas 
surprisingly, CXCL4L1 had no effect. We found the required concentration of CXCL4 to 
IV  Discussion 
 78 
exert a half maximal inhibition of endothelial cell proliferation at a micromolar level and 
thus orders of magnitude higher than the concentration of pro-inflammatory CCL5 being 
biologically effective at nanomolar levels which is in line with previous results (Gentilini 
1999). CXCL4L1 exerted endothelial chemokinesis, reflecting potential receptor binding 
and signaling differences. Plasma concentrations of CCL5 being much lower than those of 
CXCL4 reflect these distinct mechanisms since CCL5-driven chemotaxis is exerted via 
high affinity binding to G-protein coupled receptors while the mechanisms of the biologic 
effects of CXCL4 and CXCL4L1 are still incompletely understood and can not be entirely 
explained by the existence of CXCR3A and CXCR3B (von Hundelshausen 2007; Mueller 
2008). It has been shown that endothelial survival and proliferation is dependent on 
heparin-binding growth factors, most prominently VEGF which needs heparin-
like/decorated molecules for its receptor stimulating activity. The anti-VEGF activity of 
CXCL4 has been explained by direct binding to VEGF and its high affinity to heparin may 
competitively displace VEGF from cell surface heparan sulfates and VEGF receptors 
(Gengrinovitch 1995). The difference in the anti-proliferative activity between CXCL4 and 
CXCL4L1 might be explained by the absence of direct binding of CXCL4L1 to bFGF and 
VEGF. However, CXCL4 and CXCL4L1 behave similarly in this regard, as demonstrated 
by semiquantitative ligand blots. The affinity of CXCL4 to heparin-like molecules results 
in a gaugeable prolongation of the clotting time (Fiore 2003). The distinct oligomer 
distribution of CXCL4L1 and CXCL4 may be important for their distinct affinities for 
CCL5 and glycosaminoglycans. It has been shown that under physiologic pH and salt 
conditions, CXCL4 predominantly forms tetramers, which in turn form complexes with 
heparin (Rauova 2005). It is conceivable that the reduced tetramer formation of CXCL4L1 
may be one of the reasons for a decreased GAG-affinity, besides charge differences. In this 
study, CXCL4L1 showed a lower heparin-neutralizing activity as compared to CXCL4, 
indicating a lower affinity to heparin which can explain to some extent the abolished effect 
on endothelial cell proliferation by inactivating less VEGF. However, the differences in the 
primary amino acid sequence affect only the C-terminal α-helix. Initially, it was thought 
that this region, especially the lysine residues are responsible for the interaction with 
heparin (Loscalzo 1985). However, later performed NMR studies point to a minor role of 
this region (Mayo 1995) and favor arginine residues, which are located in the loops 
between the three-stranded anti-parallel β-sheet. This is in accordance with our data, since 
heparin neutralization by CXCL4L1 is still well detectable. Although CXCL4L1 exhibits 
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lower heparin neutralizing affinity than CXCL4 and has no proliferation blocking effect, it 
has a comparative effect on inhibiting angiogenesis, as determined by endothelial tube 
formation. Animal in vivo studies have shown an even stronger angiostatic activity of 
CXCL4L1 as compared to CXCL4 in a tumor model (Struyf 2007). 
Our results that CXCL4L1 less potently enhances APC generation may be due to the 
decreased affinity of CXCL4L1 to glycosaminoglycans, since this activity depends partly 
on the presence of a sulfated chondroitin moiety on thrombomodulin (Dudek 1997). Thus, 
the positive influence of CXCL4 in acute inflammatory syndromes like sepsis might not be 
exerted by CXCL4L1. 
In chronic inflammatory processes such as atherosclerosis, CXCL4 plays a proatherogenic 
role which is not yet fully understood (von Hundelshausen 2007). A potential mechanism 
resides in its enhancing effects on the subintimal recruitment of monocytes by CCL5. 
Previously, it has been shown that CCL5 induced monocyte arrest can be enhanced by 
high-affinity interaction with CXCL4, which has a considerable impact on the 
development of atherosclerotic lesions in the mouse and can be blocked by peptides 
disrupting the interaction of CXCL4 and CCL5 (von Hundelshausen 2005; Koenen 2009). 
Unlike CXCL4, CXCL4L1 failed to enhance CCL5-induced monocyte arrest which might 
be explained by the reduced affinity to CCL5. The remaining affinity of CXCL4L1 to 
CCL5 is probably due to a N-terminal interaction as observed for the CC-type of the 
CXCL4-CCL5 heterodimer (Koenen 2009). Our finding that monocyte recruitment into the 
peritoneal cavity in mice was likewise enhanced following injection of CXCL4 but not of 
CXCL4L1 indicates a minor role for CXCR3B, which does not exist in mice. 
Taken together, we identified that CXCL4L1 elicits in contrast to CXCL4 no anti-
proliferative activity on endothelial cells and neutralizes to a lesser extent heparin and 
generates less APC. However, angiostatic activity is still noted and may be explained by 
the induction of chemokinesis, impeding the correct assembly of endothelial cells in the 
process of tube formation. 
Moreover, our finding that CXCL4L1, compared to CXCL4 has a reduced affinity for 
CCL5 and heparin, may have implications for understanding of the equilibrium of both 
chemokines. CXCL4L1 may act as a homeostatic chemokine primarily as a weak 
antagonist of CXCL4 with angiostatic effects inducing random endothelial migration, 
whereas CXCL4 is the more pro-inflammatory chemokine. 
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V Summary 
 
Chemokines play an important role in the development of inflammation and in the 
recruitment of leukocytes from the vessel into the inflamed tissue. Activated platelets serve 
as a rich source of chemokines, e.g. CCL5, CXCL4 and its closely related variant 
CXCL4L1. The pro-inflammatory CCL5 is a known potent chemoattractant for monocytes 
and also responsible for its arrest on inflamed endothelium. Since this arrest is enhanced by 
the interaction of CCL5 with CXCL4, we aimed to determine the structural interaction of 
this CCL5-CXCL4 heterodimer in the first part of this thesis.  
For this purpose, CCL5, CXCL4 and CXCL4L1 were expressed recombinantly in E. coli 
by different techniques, CCL5 as inclusion bodies in the cytoplasm, CXCL4 and 
CXCL4L1 as soluble proteins in the periplasmic space. For structural analysis of the 
heterodimerization of the CCL5-CXCL4 complex, 15N-enriched CCL5 was expressed. 
Additionally, CXCL4L1 was chemically synthesized by the solid-phase peptide synthesis 
method. All generated proteins were purified by sequential steps with chromatographic 
methods using FPLC and HPLC. 
Chemical shift mapping of the 15N-CCL5 by the 15N-1H heteronuclear single quantum 
coherence (HSQC) nuclear magnetic resonance (NMR) and 3D modeling revealed that the 
N-termini were responsible for the formation of the CCL5-CXCL4 heterodimer. 
In the second part of this dissertation, a functional comparison between CXCL4 and 
CXCL4L1 was carried out to evaluate the differences of these closely related chemokines. 
This comparison revealed that the angiogenesis, as assessed by endothelial tube formation, 
was inhibited by CXCL4 as well as CXCL4L1, but only CXCL4L1 triggered undirected 
locomotion of endothelial cells (chemokinesis). The chemotactic response towards the 
growth factors VEGF and bFGF was attenuated by both variants but only CXCL4L1-
induced chemokinesis was blocked by bFGF or VEGF. Endothelial cell proliferation was 
inhibited by CXCL4 but not by CXCL4L1, while both chemokines bound directly to 
VEGF and bFGF. Moreover, CXCL4 enhanced CCL5-induced monocyte arrest in vitro 
and as well in vivo, whereas CXCL4L1 had no effect. CXCL4L1 revealed lower affinity 
for CCL5 than CXCL4 as quantified by isothermal fluorescence titration. As evidenced by 
the reduction of the activated partial thromboplastin time, CXCL4L1 exhibited less 
heparin-neutralizing activity than CXCL4. In addition, activation of protein C by 
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thrombin/thrombomodulin was less effectively accelerated by CXCL4L1 compared with 
CXCL4. It was also discovered that the C-terminal natural changes in CXCL4L1 compared 
to CXCL4 determine a different quaternary structure since CXCL4 predominantly exists as 
tetramer and CXCL4L1 as dimer under physiological conditions despite a comparable 
general positive charge. These structural differences are closely related to the different 
biological effects most prominently exemplified by the distinct effects in monocyte 
recruitment and angiogenesis. 
Summing up, CXCL4L1 may act angiostatically by causing random endothelial cell 
locomotion, disturbing directed migration towards angiogenic chemokines, serving as a 
homeostatic chemokine with a moderate structural distinction yet different functional 
profile from CXCL4. 
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VI Zusammenfassung 
 
Chemokine spielen eine wichtige Rolle bei der Entstehung von Entzündungsprozessen und 
bei der Rekrutierung von Leukozyten aus dem Gefäß in das entzündete Gewebe. Aktivierte 
Blutplättchen stellen eine wichtige Quelle für Chemokine dar, z.B. CCL5, CXCL4 und 
dessen eng verwandte Variante CXCL4L1. Das proinflammatorische Chemokin CCL5 ist 
ein auf Monozyten stark chemotaktisch wirkender Lockstoff, welcher auch deren Arrest 
auf entzündetem Endothel vermittelt. Da dieser Arrest durch die Interaktion von CCL5 mit 
CXCL4 verstärkt wird, war das Ziel im ersten Teil der Studie die strukturelle 
Wechselwirkung des CCL5-CXCL4 Heteromers aufzuklären. 
Zu diesem Zweck wurden CCL5, CXCL4 und CXCL4L1 mithilfe von unterschiedlichen 
Methoden in E. coli rekombinant exprimiert, CCL5 als Einschlusskörperchen im 
Cytoplasma, CXCL4 und CXCL4L1 als lösliche Proteine im periplasmatischen Raum. Zur 
strukturellen Analyse der CCL5-CXCL4 Heteromerisierung, wurde 15N-angereichertes 
CCL5 exprimiert. 
Des Weiteren wurde CXCL4L1 mit Hilfe der Festphasensynthese chemisch erzeugt. Alle 
so gewonnenen Proteine wurden in sequenziell aufeinanderfolgenden Schritten 
chromatographisch, mittels FPLC und HPLC, weiter aufgereinigt. 
Die chemische Verschiebung von 15N-CCL5, welche durch die HSQC-
Kernresonanzspektroskopie ermittelt wurde, und die Erstellung eines 3D Modells, machten 
die zentrale Bedeutung der N-terminalen Domänen bei der Heteromerisierung der 
Chemokine CCL5-CXCL4 deutlich. 
Im zweiten Teil dieser Arbeit wurde ein funktioneller Vergleich zwischen CXCL4 und 
CXCL4L1 durchgeführt, um die Unterschiede der eng miteinander verwandten Proteine zu 
analysieren. Dieser Vergleich zeigte, dass sowohl CXCL4 als auch CXCL4L1 die 
Angiogenese, gezeigt durch die Fähigkeit von Endothelzellen gefäßähnliche Strukturen 
auszubilden, inhibierten. Aber nur CXCL4L1 war in der Lage eine ungerichtete Migration 
der Endothelzellen (Chemokinese) auszulösen. Die chemotaktische Reaktion auf die 
Wachstumsfaktoren VEGF und bFGF wurde zwar durch beide Proteinvarianten 
vermindert, aber nur die CXCL4L1 bedingte Chemokinese konnte durch bFGF oder VEGF 
geblockt werden. Während beide Chemokinvarianten in der Lage waren an VEGF und 
bFGF direkt zu binden, inhibierte nur CXCL4 die Proliferation der Endothelzellen. 
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Darüber hinaus konnte sowohl in vitro als auch in vivo gezeigt werden, dass nur CXCL4 
den CCL5-induzierten Monozytenarrest vermittelt. 
Mittels der isothermalen Fluoreszenztitration wurde für CXCL4L1 eine geringere Affinität 
als für CXCL4 zu CCL5 nachgewiesen. Wie durch die Abnahme der aktivierten partiellen 
Thromboplastinzeit gezeigt werden konnte, weist CXCL4L1 eine schwächere Aktivität der 
Heparin-Neutralisierung als CXCL4 auf. Auch die Aktivierung von Protein C durch 
Thrombin/Thrombomodullin wurde im Vergleich zu CXCL4 durch CXCL4L1 weniger 
beschleunigt. Es konnte weiter gezeigt werden, dass die unterschiedlichen C-terminalen 
Enden auch die quartäre Struktur der beiden Proteine beeinflussen, da trotz der gleichen 
Ladung der Proteine, CXCL4 unter physiologischen Bedingungen überwiegend als 
Tetramer, aber CXCL4L1 mehrheitlich als Dimer vorhanden ist. Diese strukturellen 
Unterschiede könnten auch für die unterschiedlichen biologischen Wirkungen der 
Proteinvarianten verantwortlich sein, z.B. in der Monozytenrekrutierung und der 
Angiogenese. 
Zusammenfassend kann man vermuten, dass CXCL4L1 angiostatisch wirkt, indem es eine 
ungerichtete Lokomotion der Endothelzellen auslöst und dadurch die gerichtete Migration 
entlang eines angiogenen Chemokingradienten beeinträchtigt. Darüber hinaus stellt 
CXCL4L1 im Vergleich zu CXCL4 ein homeostatisches Chemokin mit einer leichten 
strukturellen Abweichung und dadurch veränderten funktionellen Eigenschaften dar. 
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